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ABSTRACT 
ABDULRHIM, SARA, H., Masters : June : [2020], Clinical Pharmacy and Practice 
Title: Exploring the Impact and Value of Collaborative Care Model in Diabetes Care at 
a Primary Healthcare Setting in Qatar 
Supervisor of Thesis: Ahmed Awaisu. 
 
Background: Diabetes mellitus (DM) is one of the top health priorities in Qatar 
due to its high prevalence and negative health consequences. The current prevalence of 
DM in Qatar is 15.5%, which is projected to increase to 29.7% by 2035. DM 
management is still challenging despite healthcare advancement, warranting the need 
for a comprehensive Collaborative Care Model (CCM). In an effort to deliver 
comprehensive and integrated patient-centered healthcare services in the community, 
the government of Qatar focuses on primary care. Therefore, we aim to evaluate the 
impact and value of CCM in DM care at a primary healthcare (PHC) setting in Qatar. 
 
Methodology: Phase I of this project was a multiple-time series, retrospective, 
observational study with a control group among patients with DM who received care at 
Qatar Petroleum Diabetes Clinic (QPDC) in Dukhan. The impact of CCM on glycemic 
control, blood pressure, lipid profile, and anthropometric parameters was evaluated at 
baseline and up to 17 months of follow-up. Patients were retrospectively categorized as 
intervention group if they received CCM and appropriate follow-up (n = 168) or usual 
care if they did not receive CCM and appropriate follow-up (n = 86). Quantitative data 
were analyzed descriptively and inferentially using the Statistical Package for the Social 
Sciences software. Phase II was a qualitative exploration of healthcare professionals’ 
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(HCPs’) and patients’ perspectives on the value of CCM provided at the center. Twelve 
patients and twelve HCPs participated in semi-structured one-to-one interviews. 
Qualitative data were analyzed and interpreted using a deductive coding thematic 
analysis process. 
 
Results: Patients in the intervention and control groups had similar baseline 
sociodemographic and clinical characteristics. The provision of CCM resulted in 
statistically significant improvements (p<0.05) in mean values (baseline vs. 17 months) 
of glycated hemoglobin A1c (6.9% vs. 6.5%), random blood glucose (194 mg/dL vs. 
141 mg/dL), low-density lipoprotein cholesterol (3.7 mmol/L vs. 2.8 mmol/L), total 
cholesterol (5.4 mmol/L vs. 4.3 mmol/L), weight (78.5 Kg vs. 77.9 Kg), and body mass 
index (30.4 Kg/m2 vs. 30.2 Kg/m2) over 17-months within the intervention group; 
whereas, no significant changes occurred within the control group. Similarly, the 
between group comparisons demonstrated the superiority of CCM over usual care in 
improving several clinical outcomes. The qualitative phase resulted in 14 different 
themes under the predefined domains: components of CCM (five themes), the impact 
of CCM (three themes), facilitators of CCM provision (three themes), and barriers of 
CCM provision (three themes). The majority of the participants indicated easy access 
to and communication with HCPs at QPDC. Participants appreciated the extra time 
spent with HCPs, frequent follow-up visits, and health education, which empowered 
them to self-manage DM. Generally, participants identified barriers and facilitators 
related to patients, HCPs, and healthcare system. 
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Conclusion: The implementation of CCM in a PHC setting improved several 
DM-related clinical outcomes over a 17-month period. The providers and users of CCM 
had an overall positive perception and appreciation of this model in PHC settings. 
Barriers to CCM such as unpleasant attitude and undesirable attributes of HCPs and 
patients, unsupportive hospital system, and high workload must be addressed before 
implementing the model in other PHC settings.   
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CHAPTER 1: INTRODUCTION 
Background  
Diabetes mellitus (DM) is one of the most significant global health issues of the 
21st century that affects many people worldwide (1). It contributes greatly to the 
increased prevalence of cardiovascular diseases, working-age blindness, and renal 
disease (2). The global prevalence of DM in 2019 standardized for the age group 20-79 
years was estimated to be 9.3% (463 million people) and predicted to rise to 10.9% 
(700 million people) by 2045 (3). With the global cultural and societal changes, type 2 
DM has become the most prevalent form of DM. There is a direct proportional increase 
in DM-related complications (e.g. nephropathy, retinopathy, neuropathy, stroke, and 
cardiovascular diseases) with uncontrolled DM (4,5), resulting in enormous health and 
economic burden on healthcare systems (6–8). It is estimated that USD 760 billion are 
spent globally on the management of DM per year (3), having DM complications as the 
greater contributor to the economic burden rather than DM itself (2). DM and its 
complications resulted in 4.2 million deaths in 2019 (equivalent to one death every eight 
seconds), with 46.2% of deaths associated with people under the age of 60 years 
(working age group) (3). Unfortunately, DM has become the seventh leading cause of 
death globally, accounting for over 80% of all premature deaths due to non-
communicable diseases (NCDs) (9). 
The Middle East and North Africa (MENA) region was ranked the second 
highest region globally in terms of the prevalence of DM, with a current prevalence rate 
of 12.8% that is projected to increase to 15.7% by 2045 (3). In 2019, DM-related health 
expenses in the MENA region equaled USD 24.9 billion (3). The MENA region’s 
proportion of all deaths due to DM is 53.3% in 2019 (3). The highest DM prevalence 
in the MENA region was found within the Gulf Cooperation Council (GCC) 
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countries. Kuwait had the highest prevalence (22%), followed by Saudi Arabia (18.3%) 
and Sudan (17.9%) (3). In Qatar, the prevalence of DM was 15.5% in 2019 (3), which 
is predicted to rise to 29.7% by 2035 (10). The prevalence rates of DM complications 
among Qataris between 2011 and 2013, particularly nephropathy, retinopathy, and 
neuropathy were 12.4%, 12.5%, and 9.5%, respectively (11). Within the MENA region, 
Qatar has the highest annual amount spent per patient (USD 1,751) (3). 
Despite the advancement in healthcare services globally, healthcare is still 
fragmented and complex (12) and DM management is still challenging (13,14). These 
advances in healthcare, coupled with an increase in complexity of patient illness require 
a supportive work environment to address patients’ needs and improve their health 
outcomes (15). The conventional care model, where physicians are the sole caregivers 
who address patients’ needs, is challenged to deliver holistic DM care (16,17). Various 
constraints limit the ability of primary care physicians to meet all the healthcare needs 
of patients (18). Indeed, physicians experience high workload that affects the efficiency 
of their interactions with patients, which sometimes forces them to provide suboptimal 
care to avoid patients’ irritation (19). In less than 60% of the time, physicians were able 
to appropriately educate patients about the frequency and dosing of medications and 
their adverse effects but not the duration of therapy (20). Studies also reported that in 
only 18–28% of the consultations, physicians educated patients on DM and the 
importance of self-management (21).  
 Healthcare teams involve a variety of healthcare professionals (HCPs) 
including nurses, physicians, pharmacists, dieticians, and others who share and 
combine their skills, expertise, and resources to provide comprehensive, patient-
centered care to patients with DM instead of an episodic and disjointed form of care 
(12,22–24). HCPs were globally recognized for their ability to manage up to 47% and 
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77% of chronic and preventive care, respectively (18). Traditionally, healthcare system 
organization has not supported a culture of equality among the different healthcare 
professions and the system was built on a hierarchical philosophy (25). Collaborative 
Care Model (CCM) comprises multiple HCPs with different professional backgrounds 
working together in collaboration with patients, families, caregivers, and communities 
to deliver the highest quality of care (26). A major barrier to collaboration among HCPs 
is the apparent differences in their educational preparations (27) as well as marked 
differences in their scope of practice. As the healthcare and educational system 
recognized the lack of cooperation, HCPs started to focus on effective communication, 
collaboration, and mutual respect, capitalizing on each member’s strengths and 
emphasizing on the effectiveness of team functioning (28,29). This is achieved through 
the concept of interprofessional education (IPE) and collaborative practice. Although 
each member of the healthcare team possesses a unique role, they all share a common 
mindset of patient-centeredness regardless of their diverse, yet similar, educational and 
clinical preparations. Despite the unique differences, the team approach aims to provide 
high quality and safe healthcare (30). No DM management approach, neither a novel 
oral or injectable agent nor a medical device, is as important as the services of a 
specialized DM healthcare team. 
Several reputable professional DM associations and organizations have 
recognized the importance of healthcare teamwork in managing DM. The American 
Diabetes Association (ADA) identified several strategies to improve DM management, 
including, the provision of chronic care interventions by healthcare teams and 
coordinating visits using a team-based approach during which patients with DM receive 
health education (12) and learn how to cope with DM complications (31). The synergy 
and efficiency of healthcare teams are facilitated by the participation of HCPs, patients, 
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and their families (32). Accordingly, well-organized multidisciplinary teams reduce 
HCPs’ burnout and increase patient satisfaction (18). Having compassionate HCPs in 
the DM healthcare teams promotes effective patient guidance, behavioral change, and 
adherence to medications. Indeed, patients were more likely to disclose nonadherence 
behavior when dealing with compassionate HCPs (20).  
There is a substantial body of evidence highlighting the positive impact of CCM 
in reducing medical errors and improving patients and health system outcomes 
(6,12,16,33–36). Education and self-management support provided by nurse 
practitioners as part of a collaborative team helped 50% of patients to achieve target 
glycated hemoglobin A1c (HbA1c), 95.6% to achieve a target systolic and diastolic blood 
pressure (BP), and 57.8% to achieve target low-density lipoprotein cholesterol (LDL-
C) (37,38). Similarly, the addition of pharmacists to the healthcare team reduced HbA1c, 
fasting blood glucose (FBG), body mass index (BMI), weight, BP, hospitalizations, risk 
of DM-related complications, and mortality (39–42) as well as improved patients’ 
knowledge about DM and its complications, its treatment, self- monitoring (7), and 
their quality of life (QoL) (33,43,44). Although the value of each healthcare team 
member is well-recognized globally, multidisciplinary team collaboration in primary 
healthcare (PHC) settings is still underutilized due to non-referral and lack of perceived 
need for the service (45). 
The priorities of healthcare systems have shifted significantly from a reactive 
approach to a proactive one in many chronic diseases management in PHC settings to 
improve population health by preventing emergency department utilization for non-
emergent or preventable situations and reducing readmissions after hospital discharge 
(20). A substantial proportion of preventable emergency department utilization by 
patients with DM was due to insulin-related decompensations that directly reflects poor 
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medication self-management and medication nonadherence (20). These preventable 
emergency and secondary care visits can be appropriately addressed in PHC settings.  
The magnitude of the burden of NCDs means that the management of these 
diseases by specialists or hospitals alone is no longer feasible (46). Individuals with or 
at risk of developing NCDs require proactive, individualized, and continuous 
healthcare, which can only be given equitably by PHC providers (47). PHC settings are 
the most suitable for chronic diseases management as they provide continuity of care 
and information sharing to aid the coordination of patient care and support in medical 
decision-making (47). PHC centers offer the greatest potential to detect and screen 
people at high risk and offer the possibility to prevent the progression of disease (46). 
The large number of patients with DM may potentially overwhelm referral systems, 
resulting in high cost for both the individuals and the healthcare system. Hence, PHC 
is a practical, effective, and equitable option for patients with DM who are in need of 
healthcare (46).  
Qatar has long recognized the importance of DM management in PHC settings. 
Several national strategies were developed to address this issue. For example, the Qatar 
National Health Strategy 2018-2022 aims to provide a comprehensive healthcare 
system through different strategies, including the National Primary Care Strategy 2013-
2018 and the Qatar National Diabetes Strategy 2016-2022 (48). The latter two strategies 
assure DM health promotion, education, and counseling (48) within a comprehensive, 
integrated, and person-centered PHC services provided in partnership with individuals, 
families, and communities to advance health and well-being (48).  
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Study Rationale 
Healthcare has been shown to be delivered in segregation by individual 
members of the healthcare team rather than collaboratively (21). Promoting a shared 
healthcare vision is not a new concept, and fostering of a collaborative work 
environment has been the driving force behind healthcare delivery for decades (21) in 
acute healthcare settings, but not in PHC settings (49). There is a dearth of literature on 
the need for a collaborative healthcare practice to address the needs of patients with 
complex and chronic health conditions (50). Although global evidence supports the 
positive impact of CCM offered for patients with DM in PHC settings, it is unknown if 
such interventions would improve patient outcomes in a PHC setting in Qatar. 
Furthermore, the perspective of HCPs and patients regarding the value of CCM in DM 
management in PHC settings in Qatar is unknown. To our knowledge, there were no 
previous studies in Qatar investigating the impact of CCM on DM outcomes and the 
perspectives of HCPs and patients regarding CCM’s value in PHC settings. 
 
Research Questions 
Phase I:  
• What is the impact of CCM on the outcomes of patients with DM followed-up in 
PHC settings?  
• Are there differences between pre- and post-intervention delivered by the 
collaborative healthcare team on selected outcome measures?  
Phase II: 
• What is the perception of HCPs and patients on the value of CCM on DM care in 
PHC settings?  
• What are the facilitators and the barriers to the provision of CCM in PHC settings 
  
 
 
7 
and practical solutions to tackle them? 
 
Study Objectives  
The overall objective of this study was to explore the value of CCM and its impact 
on DM outcomes in PHC settings in Qatar. The project was conducted in two phases: Phase 
I was a quantitative collection of patient data through electronic medical records, while 
Phase II focused on the qualitative assessment of the value of CCM.  
 
Specific Objectives for Phase I 
I. To characterize the clinical profile including DM-related comorbidities and 
complications of patients with DM attending an ambulatory DM care clinic at a 
PHC center. 
II. To evaluate the impact of CCM on glycemic control (HbA1c and FBG) among these 
patients. 
III. To evaluate the impact of the CCM on other disease-related outcomes comprising 
lipid profile, BP, and body mass index (BMI). 
 
Specific Objectives for Phase II 
I. To explore the perspectives of HCPs and patients regarding the value of CCM in 
DM management in PHC settings. 
II. To determine the facilitators and the barriers to the optimal application of CCM in 
DM management in PHC settings. 
 
Study Significance 
In general, there is a lack of data about the benefits of providing CCM to patients 
with DM in PHC settings in Qatar. This study will describe the components of the CCM 
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provided by HCPs in Qatar Petroleum Diabetes Clinic (QPDC), which can guide in the 
implementation of CCM in ambulatory settings if proven to be effective. Managing and 
controlling DM will help in reducing the complications, risks of hospitalizations, and 
medication overuse associated with the disease, resulting in cost-savings and better 
resource utilization.  
This study is targeting a national priority in Qatar as per the Qatar National Health 
Strategy that emphasizes patient-centered care provision (51,52). The study will also 
promote a research culture in the PHC settings and therefore contribute to evidence-based 
practice. 
Dissemination of the project findings to stakeholders (health-policy makers, 
primary care HCPs who manage patients, and patients) with recommendations on how to 
improve CCM provision will draw more attention to the impact of interprofessional 
collaboration and education and will lead to optimal utilization of this care model.  
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CHAPTER 2: LITERATURE REVIEW 
Background 
This chapter presents a review of the literature about the impact of CCM on DM 
outcomes in PHC settings and the perspectives of stakeholders (HCPs and patients) on 
the value of such care. The chapter starts with an introductory section about the different 
terminologies used to describe interprofessional collaboration among HCPs, followed 
by a review of the collaborative care competencies with a particular emphasis on 
communication, an important competency that is often overlooked in the literature. 
Furthermore, a thorough presentation of the impact of the involvement of different 
HCPs to the healthcare team on DM outcomes is presented.  
 
Definitions and Terminologies Associated with Collaborative Care 
The culture and practice of collaborative care begins with IPE, a foundation that 
starts in HCP education programs. According to World Health Organization (WHO), 
"Interprofessional education occurs when students from two or more professions learn 
about, from and with each other to enable effective collaboration and improve health 
outcomes" (26).  Therefore, IPE provides an opportunity for HCP students to learn 
“about, with, and from each other” to improve collaboration and quality of patient care 
when they move into practice (53). It is believed that when these students graduate and 
join clinical practice, they will be able to translate the skills gained from IPE into 
collaborative practice.  
The College of Pharmacy at Qatar University has implemented several IPE 
initiatives that meet international accreditation requirements (54). HCPs in Qatar  had 
a positive attitude towards these IPE initiatives, which is essential to successful 
implementation of interprofessional collaboration (55). Although relatively much has 
been reported about IPE in Qatar, the literature pertaining interprofessional practice in 
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Qatar is limited. 
There are various terms used to represent collaboration among HCPs that 
indicates a lack of consistency or consensus in their usage in literature (56). These terms 
include intraprofessional, multidisciplinary, multiprofessional, interdisciplinary, 
interprofessional, transdisciplinary, and transprofessional collaboration. Some of these 
terms have a visible distinction and use, while others are usually used interchangeably. 
Agreement on terminology to describe collaboration among HCPs seems essential to 
serve as a shared basis for education, research, and practice (56).  
Disciplines are described as “individual sciences that study different subjects 
independently of each other”, while professions are defined as “a service occupation 
relevant to society” (56). A profession links between theory and practice by applying 
the scientific knowledge of a particular discipline in actual practice settings (56). The 
term profession is thus used for practically applied disciplines: medicine is a discipline; 
a physician represents a profession (56).  
The prefixes “multi”, “inter” and “trans” refer to the nature or intensity of the 
collaboration. The cooperation within a single profession is denoted as 
intraprofessional collaboration (56). Multidisciplinary collaboration means the 
involvement of more than one discipline in one activity (57). Multiprofessional 
collaboration describes the cooperative work of several professions together, but most 
of the time, they practice independently (56). Interdisciplinary collaboration designates 
the overlap of scientific fields, whereas interprofessional collaboration represents the 
sharing of skills, expertise, and diagnostic modalities among different professions to 
collectively achieve better outcomes (12). The latter two terms are used in the literature 
frequently and interchangeably, even within a single article, especially in the literature 
of the collaboration of physicians with other HCPs (56). Transdisciplinary practice is 
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when students from diverse disciplines utilize their unique knowledge and skills and 
apply them in a specific setting (58). When HCPs jointly communicate, exchange ideas, 
and work together from the beginning to address patients’ needs, then this form of 
teamwork is called transprofessional collaboration (56). Other terms like team-based 
care represent a group of various professionals collaborating regularly about the care of 
a specific group of patients (e.g. PHC team, operating room team, etc.) (12,59).  
 
Collaborative Care Competencies 
Collaborative care competencies assure the integration of knowledge, skills, 
values, and attitudes that aid team working within and among professions, and with 
patients and their families to improve health outcomes (59). Setting competencies is 
needed to facilitate professionals’ lifelong learning, evaluate the difference between 
interprofessional educational core competencies and practice needs, and inform 
professional credentialing bodies in defining potential testing content for collaborative 
practice. There are several types of competencies from an interprofessional perspective 
(Figure 1). “Common” competencies are those expected of all healthcare professionals. 
“Complementary” competencies enhance the qualities of other professions in providing 
overlapped care. “Collaborative” competencies are those needed by each profession in 
order to work with other professions, patients, families, and communities (60,61). A 
particular focus on collaborative competencies will be discussed in this chapter. 
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Figure 1. Types of collaborative competencies. 
Source: Barr’s (1998) 
 
 The Institute of Medicine (US) Committee on the Health Professions Education 
has proposed a set of core competencies that should be possessed by all HCPs to meet 
the needs of the 21st century patients (61). These competencies include providing 
patient-centered care, working in interdisciplinary teams, employing evidence-based 
practice, applying quality improvement, and utilizing informatics in effective 
communication (Figure 2) (61). 
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Figure 2. Overlap of care competencies for health professions.  
Source: The Institute of Medicine (2003) 
 
Effective communication among HCPs aids in enhancing the clarity within the 
team, anticipating and avoiding medical errors, improving service provision, and 
promoting continuity of care (62,63). Owing to the unique communication approach of 
each profession, accurate decision-making requires the sharing of patients’ information 
at the right time through the appropriate communication with other team members (12). 
In the absence of face-to-face communication among HCPs, electronic health record 
(EHR) serves as a tool to ensure appropriate collection and sharing of patients’ health 
data, thus, the provision of patient-focused care (12). Moreover, EHRs enable HCPs to 
perform an in-depth analysis of the processes by tracking patient outcomes to determine 
the efficacy of CCM (12,30). Fortunately, patients with poor health outcomes and 
infrequent follow-up visits can be easily detected through EHRs (20). Despite the 
benefits of patient records, the patient-provider relationship can be affected by EHRs. 
Physicians are obliged to enter patient data into EHRs, which may compromise the time 
allocated for clinical interaction and the quality of patient-centered communication, 
especially for clinicians with poor communication and computer skills (20). Although 
communication is a crucial aspect of CCM, the literature rarely discusses means of 
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communication, as reported by one systematic review (SR) (21). 
 
Interprofessional Collaborative Team Composition and Role Clarification  
 No single professional discipline has the capacity and the ability to efficiently 
address the complex healthcare needs of all patients with DM. Complex healthcare 
needs require continuous management that is obtainable from a wide range of HCPs. 
There are many other healthcare professionals, besides physicians, who have a valuable 
role in DM management. Nurse practitioners, pharmacists, podiatrists, optometrists, 
dietitians, certified DM educators, case managers, social workers, mental health 
professionals, and other professionals’ addition to the healthcare team were deemed 
beneficial (12). Appropriate collaboration between physicians and the above-
mentioned professionals who possess varied and unique expertise may significantly 
improve DM management to not only include treatment provision and counseling, but 
also address self-care, lifestyle habits, and prevention of complications (12,21). 
Moreover, a significant reduction in the percentage of patients with no improvement in 
HbA1c was reported in the literature as a result of equal discipline participation without 
a designated leader (30). 
The literature has not specified a fixed number or composition of collaborative 
healthcare teams, but the goal is to utilize the necessary HCPs for individualized patient 
cases efficiently. Healthcare team composition typology was comprehensively reported 
in a SR of 109 articles (64). The types mentioned in the review include, but not limited 
to, specialized teams of a primary care physician and a specialist, multidisciplinary 
teams of a physician–nurse duo, and physician–nurse–pharmacist triad (64). 
In the same SR, the authors have identified three roles within the healthcare 
team as the most relevant in primary care: the clinical leader, the case manager, and the 
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expert consultant (64). Physicians and pharmacists usually fulfill the clinical leader 
role, especially in cardiovascular-related diseases and medication management, 
respectively (65,66). The second role aims to improve usual practice by coordinating 
healthcare teams, monitoring patients’ progress (67,68), counseling patients, ensuring 
adherence to medications (67,69), and empowering patients to self-monitor their 
condition (70). Nurses have been commonly reported in the literature as case managers 
for the healthcare team (71,72). The role of the expert consultant is particularly 
prominent in the care of elderly patients who have a high prevalence of comorbid and 
psychological conditions, thus, demand for the intervention of geriatricians (73,74) and 
psychiatrists or psychologists to serve (67,75–77). 
 
Profession-Specific Role and Impact on Diabetes Outcomes 
One critical component of facilitating a collaborative working relationship 
among HCPs is to understand the roles and responsibilities of other members of the 
healthcare team (20). Role clarification was identified as a critical feature for 
developing strong interprofessional relationships by various collaborative care 
competency frameworks (78,79). Role clarification means that HCPs recognize and 
respect other practitioners’ roles and scope of practice (80). Confusion about other 
HCPs overlapping role and their applications can lead to conflict and lack of trust (81). 
Avoiding the occurrence of such confusion requires the participation of all HCPs in 
regular team meetings that allow them to negotiate a mutual understanding of their roles 
and functions in order to build a better working relationship and set common goals (23). 
In the upcoming sections, the role and impact of selected HCPs will be discussed. 
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Nurse 
Nurses hold a central role in collaborative healthcare teams to provide safe, 
efficient, and effective patient-centered care to patients with complex health conditions 
(82). They are recognized as key players in the development of policies, 
implementation of change, provision and coordination of patient care, and measurement 
of healthcare improvement (12,23). Certified nurses as diabetes educators have 
specialized knowledge in DM and offer support and advice between appointments on 
lifestyle changes and blood glucose (BG) monitoring to patients with DM (12). The 
literature is supporting the involvement of certified diabetes nurse educator in the 
primary care teams as they enhance the link among HCPs, participate in the prevention 
of DM, and guide patients on self-monitoring leading to reduction in DM long-term 
risks (83), including hospital readmissions (84).   
 
Diabetes Case Manager 
Case managers are assigned the authority to oversee, coordinate, and implement 
care (85). The literature showed that case managers were able to close the physician-
identified knowledge gaps between patients diagnosed with DM and their attendance 
to DM clinics (83). Case managers ensure the adaption of evidence-based practice, 
promotion of advancement of DM therapy management, and support of patients’ self-
management practices (83,86), leading to meaningful improvement in glycemic control 
(87,88).  
 
Counselor and Social Worker 
The majority of DM management guidelines overlook the psychological need 
of patients with DM while focusing exclusively on the medical aspect of the initial 
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management (89). DM impact the psychological and social wellbeing of individuals 
living with it, consequently impacting one’s ability to manage DM. Therefore, 
managing the psychological and emotional side of DM is very critical. Counselor and 
social worker are examples of health workers who can address the psychological needs 
of patients with DM (90).  
Counselors explain various health options to patients and empower them to set 
achievable goals that will ultimately lead to appropriate action-taking (91). Studies have 
shown that DM counselors led to significant improvement in patients’ postprandial 
blood glucose levels and a reduction in their lipid profile (91). Social workers help 
patients overcome social determinants of health including stressful life events, 
relationship conflicts, disabilities, violence, inadequate housing, and work problems via 
a variety of techniques (e.g. mindfulness and narrative therapy) (92). Patients who meet 
social workers have greater reductions in HbA1c and LDL compared to patients who do 
not (92). 
 
Pharmacist 
Pharmacist's role was traditionally restricted to medication dispensing. 
However, pharmacists now have the opportunity to participate in direct patient care as 
part of healthcare teams, particularly in chronic diseases management (93). Pharmacists 
and DM educator pharmacists are instrumental in the management of patients with DM 
because of their ability to provide disease education, medication therapy management, 
and promote patient medication adherence. They can also support physicians and nurses 
by providing evidence-based drug therapy recommendations and serving as a drug 
information resource (94). Engaging pharmacists in the healthcare team were shown to 
significantly improve FBG, HbA1c, and BMI and enhance patients’ understanding of 
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diseases, medications, and self-care activities (12,95,96).  
 
The Impact of Pharmacist Care on Diabetes Outcomes in Primary Care Settings: An 
Umbrella Review of Published Systematic Reviews 
A comprehensive umbrella review of published systematic reviews (SRs) was 
conducted to investigate the impact of adding a pharmacist to the healthcare team on 
DM outcomes in PHC settings (97). PubMed, EMBASE, Scopus, Database of Abstracts 
of Reviews of Effects, Cochrane Library, Joanna Briggs Institute (JBI) Database, 
Google Scholar, and PROSPERO were searched using the following terms combined 
using Boolean connectors (AND/OR): (pharmac*, multidisciplinary, collaborat*, 
interprofessional) AND (care, service, intervention) AND (DM, diabetes mellitus, type 
1 DM, type 2 DM) AND (primary care, primary healthcare, ambulatory, outpatients, 
community) AND (systemati* review, meta-analysis, summary, narrative, literature, 
review, overview, rapid review, scoping review, umbrella review).  
Reviews were included if they reported one or more of the following outcomes: 
clinical outcomes (HbA1c, FBG, body weight, BMI, BP, lipid profile [LDL-C, high-
density lipoprotein cholesterol (HDL-C), triglycerides (TG), total cholesterol (TC)], 
humanistic outcomes (QoL, satisfaction with pharmacist interventions, perception 
regarding pharmacist interventions), and economic outcomes (cost-benefit and cost 
savings resulting from the pharmacist intervention).  
The initial search identified 1,134 hits from the electronic databases. Out of the 
1,134 articles, 89 duplicates were removed. Of the remaining 1,045 hits, 23 articles 
were potentially eligible for inclusion based on title and abstract screening. Sixteen 
articles were excluded for one of the following reasons: service not provided in a PHC 
setting, not focused on DM, or not focused on pharmacist interventions. 
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The exact role of the pharmacist in the multidisciplinary team or the nature of 
the intervention provided to patients with DM in PHC settings, being pharmacist-led or 
pharmacist-involved interventions, widely varied among the reviews. All of the seven 
SRs categorized the service as either pharmacist-led or pharmacist-involved DM care 
in PHC settings, except one review (98) that did not categorize the nature or extent of 
the service despite the inclusion of pharmacists in the healthcare team. Four SRs (98–
101) reported the nature of pharmacist interventions, of which only one (100) conducted 
and published a meta-analysis of the impact of each intervention on HbA1c. Educational 
and clinical interventions by pharmacists were the most common types of interventions 
reported across SRs. A framework of the various pharmacist interventions in DM care 
at PHC settings reported in the included reviews is illustrated in Figure 3.  
 
  
 
 
20 
 
Figure 3. A framework of pharmacist interventions in DM care in primary healthcare 
settings. 
 
Improvements in HbA1c was the most reported clinical outcome of pharmacist 
intervention in the literature (39,98,100–103). Only one (99) of these reviews did not 
report HbA1c as a clinical outcome, but reported improvements in medication-related 
problems, morbidity, and mortality instead. Pharmacist interventions also resulted in 
favorable significant improvements in FBG, BP, BMI, LDL-C, HDL-C, TC, and TG in 
more than 50% of the SRs.  
Humanistic outcomes including QoL were evaluated by three SRs (99,100,103), 
and patients’ attitude towards pharmacy services was assessed by one SR (102). 
However, one SR (99) reported a lack of benefit of DM care by pharmacists on patients’ 
QoL and satisfaction with the service provided. Due to the variability in the type and 
nature of humanistic outcomes assessment tools (generic versus disease-specific) 
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among primary studies, the authors were unable to draw a final conclusion. 
Only three SRs (98,99,102) assessed the impact of pharmacist interventions on 
DM-related economic outcomes. One of these reviews showed that pharmacist 
interventions resulted in significant cost-saving (ranging from $8-$85,000 per person 
per year) as well as significant service cost beneficence (benefit-to-cost ratio ranging 
from 1:1 to 8.5:1) according to the 2014 US dollar (98). The other two reviews reported 
simple cost analyses. 
 
Perspectives of Healthcare Providers and Patients on the Value of Collaborative Care 
in Diabetes Management 
The perceptions of CCM providers (i.e. HCPs) and recipients (i.e. patients with 
DM) have been inadequately investigated and reported in the literature. A qualitative 
study showed that physicians perceived interprofessional teamwork as an enabling 
factor for delegating patient education to nurses and DM educators and monitoring DM 
medications to pharmacists (104). Physicians valued the positive impact of engaging 
other HCPs in medication management represented in the delegation of medication 
monitoring and consultations to other HCPs as well as improved patient knowledge and 
health outcomes (19,105). Nevertheless, pharmacists also expressed that working in a 
team that includes community health workers had produced positive clinical outcomes 
in patients with uncontrolled DM (104).  
Some patients with DM felt that there is no need to seek further engagement 
with other HCPs as their healthcare needs were adequately met by one HCP (106). 
However, patients had a favorable opinion about and high satisfaction with their disease 
management and collaborative treatment after participating in the CCM (37,106,107). 
Moreover, patients receiving CCM appreciated the additional time spent with the 
general practice nurse (37).  
  
 
 
22 
As a conclusion to this chapter, DM is a complex chronic disease that cannot be 
adequately managed by a single healthcare profession. Optimal DM management 
requires the valuable input of each member of the healthcare team. Healthcare settings 
requiring multiple practitioners to collaborate and support patient care can benefit from 
additional evidence showing the benefits of collaboration and collaborative efforts. 
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CHAPTER 3: METHODS 
 Phase I: The Impact of a Collaborative Care Model in Diabetes Management 
in a Primary Healthcare Setting 
Study Design 
This phase was a multiple-time series, retrospective, observational single-center 
study with a control group among patients with DM who attended QPDC. EHR clinical 
data of patients with DM attending QPDC were retrieved retrospectively. The study 
design is illustrated in Figure 4, where “O” denotes outcome measures, “X” denotes 
CCM provision, and “~X” denotes usual care (no CCM).  
 
 
Figure 4. Multiple-time series study design. 
 
Study Setting  
This study was conducted at the QPDC in Dukhan. QPDC was established in 
2007 as part of Qatar Petroleum Medical Center (QPMC) in Dukhan. QPMC offers a 
variety of healthcare services to QP employees and their families, and other members 
of the community including Qataris and residents. To our knowledge, the QPDC is the 
only specialized clinic in Qatar where HCPs optimally offer CCM since 2007 for 
patients with DM. QPDC operates on Mondays and Wednesdays, with an open walk-
in policy.  
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The clinic is staffed by a multidisciplinary team consisting of physicians, 
nurses, and pharmacists who have an adequate educational background and 
professional experiences in DM management. The DM team typically provides 
personalized patient education, develop treatment priorities, and design appropriate 
action plans in consultation with the patient. Patients attend individualized and regular 
follow-up visits at least every month. The patients are not allocated a specific time for 
consultation, but consultations rarely exceed 30-40 minutes compared to inadequate 20 
minutes consultations at other PHC centers across the country with minimal interaction 
with nurses and pharmacists. During these consultations, patients receive 
comprehensive and standardized management for DM including screening of DM, 
routine assessment and treatment, and early detection and care of complications such 
as neuropathy, retinopathy, nephropathy, and cardiovascular diseases. More details 
about how collaborative care is provided in QPDC Dukhan are provided under 
“Description of Collaborative Care Model versus Usual Care at QPDC”.  
 
Study Population and Eligibility Criteria 
The study included all adult patients (18 years or older) diagnosed with type 2 
DM and followed up at QPDC. Patients were included in the study regardless of their 
DM-related complications, comorbidities, and adherence to the treatment plan to 
eliminate the influence of external factors on patients’ progress beyond the clinical 
team’s collaboration patterns.  
 
Sample Size and Sampling Technique 
G-Power® software computed a sample size of 82 patients based on an effect 
size of 0.4% difference in HbA1c, an alpha of 0.05, and a power of 90%. After adding 
  
 
 
25 
20% of patients to account for missing or incomplete data, the sample size per group 
increased to ~100 patients. However, we applied universal sampling approach to 
include all patients who satisfied the previously stated eligibility criteria. Therefore, 
there was no specific sampling technique applied in selecting the subjects included in 
the analysis. 
 
Description of Collaborative Care Model versus Usual Care at Qatar Petroleum 
Diabetes Clinic  
Healthcare Professionals’ Qualifications 
Physicians at QPDC are well aware of the importance of CCM in DM 
management. Therefore, they are open to suggestions and discussions with other HCPs 
for the benefit of the patients. The nurse is a certified DM educator practicing in this 
clinic since 2007. The pharmacist has at least 10 years of experience practicing in this 
setting and has relevant credentials in DM education and providing direct patient care 
functions. HCPs follow QP company’s work ethics and policies, serving as a guideline 
and a reminder to HCPs. A scanned copy of these documents is available in Appendix 
F.  
 
Continuous Professional Development 
At QPDC, one-hour long continuous professional development (CPD) sessions 
are conducted weekly to update the HCPs regarding various health topics. The HCP 
staff have the autonomy to recommend specific topics as well. HCPs’ performance on 
CPD topics is assessed via a pre-post quiz in order for them to receive continuous 
education and license renewal points. QP CPD sessions are independent of those 
offered at Hamad Medical Corporation (HMC). However, they are accredited and 
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approved by Qatar Council for Healthcare Practitioners (QCHP). HCPs at QPDC can 
also attend CPD events at other institutions such as HMC (108) and Qatar University 
(QU) (109).  
 
Shared Medical Appointments 
Due to the growing demand for high-quality healthcare services, HCPs are 
pressured to meet more patients per day, which reduces the time allocated per patient 
to as short as 10-17 minutes (110). Consequently, HCPs briefly consult patients on 
numerous aspects of DM, up to 17 topics, in 17 minutes (110). The rushed medical 
services cannot offer sufficient health education and counseling to patients with DM. 
Shared medical appointments, as practiced in QPDC, addresses the various medical and 
educational needs of patients with DM in a single appointment instead of scheduling a 
separate appointment with each HCP (111).  
 
Process of Care 
The process of care at QPDC starts with patient’s contact with the pharmacist. 
The patient handles his/her glucometer to the pharmacist to print the BG data stored in 
the device. The pharmacist gives encouraging phrases like “perfect readings; excellent; 
continue the same diet and lifestyle” to patients who show improvement in their BG 
reading, and comfort patient who do not, by saying “we will help you control your BG; 
you need to improve your lifestyle”. The monthly and weekly glucometer data is saved 
on the system by the pharmacist for sharing information with other HCPs. Then, 
patients handle their reports to the specialized nurse educator.  
The nurse provides a brief focused consultation on health and lifestyle as well 
as examinations of anthropometric parameters and laboratory tests. The nurse assists 
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patients in self-evaluating BG reading by highlighting the above-target, within-target, 
and below-target readings.  
The patient then meets with the physician for further assessment and initiation, 
refill, or modification of medication therapy, as appropriate. Physicians initiate the 
collaboration process by referring patients, especially those with uncontrolled DM, 
back to the pharmacist for DM management and non-didactic health education. Finally, 
the patient ends with seeing the pharmacist again for thorough medication 
reconciliation and assessment of the patient’s health status and lab results. After 
reviewing the medication list, BG log, and laboratory values, the pharmacist provides 
guideline-directed therapeutic recommendations to the provider to add, stop, or change 
doses of any oral or injectable medications per the current clinical guideline for type 2 
DM management. After the discussion, the pharmacist implements a suitable 
therapeutic plan for the patient. In addition, the pharmacist assesses patients’ DM 
knowledge, level of DM self-care, and lifestyle habits and educate the patient on the 
treatment plan, lifestyle adjustment, acute management protocols, and self-
management of the disease. The self-management advice at QPDC closely aligned with 
the reported theoretical framework of interventions for patient-self management of type 
2 DM in Qatar (112) (Figure 5). The HCPs also address other comorbidities in each 
visit including hypertension, dyslipidemia, and obesity for comprehensive 
cardiometabolic management.  
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Figure 5. A theoretical framework of interventions for patient-self management of type 
2 DM in Doha, Qatar. 
Source: Mohamed (2013) 
 
This collaborative practice demonstrated a work-load shift that appropriately 
utilizes the potentials of nurses and pharmacists without compromising the patient-
physician relationship.  
 
Family Education 
HCPs in QPDC provide patient and family education on DM, medications, and 
lifestyle changes using various tools including pictograms and audiovisuals (100-inches 
high-resolution television monitor). What is unique about this clinic is the use of visuals 
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including posters on the clinic walls that illustrate all aspects of DM and the negative 
impact of DM on body systems. Such tools aid in engaging family members in support 
of the patients. 
 
The Use of Telehealth (Telephone Follow-up) at QPDC 
The 2018 Diabetes Canada Clinical Practice Guidelines recommend the use of 
telehealth in disease management (113). Telehealth is defined as the delivery of 
healthcare to patients without an in-person meeting (e.g. a telephone call). Telehealth 
facilitates patients access to expert DM care (114). At QPDC, the pharmacist provides 
telephone follow-up 24 hours, all days of the week, for all patients.  
 
Study Groups 
Patients receiving collaborative care in QPDC Dukhan from the physician, 
pharmacist, and nurse were included in the intervention group. In other words, patients 
who received the full process of care mentioned under the “process of care” section as 
described above are included in the intervention group, whereas patients who received 
the usual care provided by physicians only were included in the control group. The 
control group patients mainly visit QPDC to receive medication refills and basic 
instructions on medications use by pharmacists. Regardless of study groups, all patients 
receive at least an annual DM eye screening, renal function test, and foot examination. 
In addition, patients are also checked for other aspects of DM care including depression 
and annual influenza and pneumococcal vaccination status.  
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Outcome Measures 
 Thirty-four indicators were utilized in the literature to evaluate DM outcomes: 
fourteen indicators for glycemic control, two indicators for early detection of glycemic 
complications, four indicators for treatment of glycemic complications, eleven 
indicators for cardiovascular diseases, and three indicators of QoL (115). However, 
HbA1c is considered the primary clinical indicator of DM control as per ADA; thus, 
HbA1c was set as the primary outcome measure in this study (95) as it represents the 
glycemic history of the patient over the preceding 120 days (116). The frequency of the 
HbA1c test depends on the patient’s status, the treatment used, and medical judgment 
(30). Other outcomes that were collected in the study were FBG, random BG (RBG), 
BP, LDL-C, HDL-C, TG, TC, weight, and BMI.  The data were collected starting from 
the first measurement of each patient (i.e. individualized baseline), meaning that not all 
patients have the same calendar service start date. The outcomes data were collected 
for the subsequent 17 months from the baseline, followed by averaging the values of 
each outcome every 6 months (i.e. 6-months, 12-months, and 17-months) to account 
for missing data and ease the data analysis process. This corresponds with the averaged 
values from months 1-6, 7-12, and 13-17, respectively. 
 
Data Source 
 Retrospective data for this study were directly obtained from the electronic 
Medical Information Management System (MIMS), the available EHR at QPDC. 
MIMS is an automated information system that manages all data related to patient care 
activities (117). Therefore, this study primarily aimed to determine the impact of 
collaborative care on the clinical outcomes of DM at a PHC center in Qatar, which can 
be described as a real-world study that involves pragmatic real-word data (RWD).  
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Real-world studies have become increasingly recognized for their power to 
provide evidence of treatment effectiveness in clinical practice. While randomized 
clinical trials (RCTs) are the ‘‘gold standard’’ for evaluating safety and efficacy of new 
therapeutic interventions, unavoidably strict inclusion and exclusion criteria may result 
in the selection of non-representative study participants that may considerably differ 
from the encountered patients in the actual clinical settings or real-world practices 
(118). 
Data sources used in observational studies have expanded to include RWD as it 
strengthens observational research methodology (119). RWD is defined as “data 
obtained outside the context of RCTs, generated during routine clinical practice” (120). 
EHR, claim databases, and prospective or retrospective observations of diverse patient 
populations can be used to obtain RWD (118). Currently, most regulatory bodies and 
health organizations use real‐world evidence (RWE) derived from analyzing RWD to 
improve healthcare decision-making. RWD is best suited for studies that evaluate the 
presence or absence of a pre-specified effect and its magnitude in a specific population. 
The results might lead to treatment recommendations if the RWE shows similar results 
to RCT despite the uncontrolled environment (120).  Therefore, for phase I of the 
project, RWD retrieved from patients’ EHRs were used as the data source owing to 
their representativeness of the actual study population over RCTs. 
The joint International Society for Pharmacoeconomics and Outcomes Research 
(ISPOR) and the International Society for Pharmacoepidemiology (ISPE) Special Task 
Force have identified seven recommendations to enhance the planning, conduct, and 
dissemination of studies using RWD (Figure 6) (120). These recommendations reassure 
the integrity of RWE and enhance the public and policy-makers confidence in RWE 
(120). The “✓” and “✗” symbols are used to indicate met and unmet criteria, 
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respectively. Project publication (recommendation 3) and replication (recommendation 
4) as well as addressing methodological criticisms (recommendation 6) will be fulfilled 
in the future (“     ” symbol).  
 
 
Figure 6. Recommendations for good procedural practices for the hypothesis 
evaluating treatment effectiveness studies. 
 
 
 
✓ 
✓ 
✓ 
✗ 
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Study Instruments 
A comprehensive data extraction/collection sheet was developed to collect the 
outcomes of interest from the patients’ EHR (see Appendix A). The instrument was 
then validated using the opinion of two thesis supervisors and three HCPs at QPDC and 
piloted during the data collection phase. Two amendments were applied to the 
instrument to capture the clinical data from the patients’ profiles better.  
 
Data Collection Procedures 
Anonymous data collection of patients’ socio-demographics (age, gender, type 
of DM, smoking and alcohol consumption), clinical characteristics (past medical and 
medication histories), laboratory investigations, and DM-related outcome measures 
(FBG, HbA1c, RBG, BP, lipid profile, and anthropometrics) was ensured. Therefore, all 
patient identifiers such as names, ID numbers, and date of birth were removed to ensure 
anonymity. Each subject was assigned a unique research code. The outcomes were 
retrieved from MIMS using the previously developed data collection form. The data 
were extracted to and coded on a Microsoft (MS®) Excel sheet and later migrated to 
IBM Statistical Package for Social Sciences (IBM SPSS®, version 26.0; IBM Corp, 
Armonk, NY, USA).  
 
Statistical Analyses 
Data were analyzed using SPSS® and MS® Excel. Both descriptive and 
inferential statistics were applied as appropriate. Summary of statistics including 
frequencies (%), mean ± SD, and median (IQR) were used appropriately to describe the 
demographic and clinical characteristics of the patients in both groups. Chi-square and 
Fisher’s Exact tests were used to compare categorical outcome variables between the 
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two groups. For normally distributed variables, independent t- and repeated measures 
analysis of variance (ANOVA) tests were used, while Mann-Whitney U- and Friedman 
tests were used for non-normally distributed variables. Independent t- and Mann-
Whitney U- tests were used for between-group analyses, whereas repeated measures 
ANOVA and Friedman tests were used for within-group analyses to determine the 
impact of the CCM on continuous variables. Comparisons were carried out using a 
significance level of < 0.05 (two-sided p-value). 
 
Ethical Considerations 
The QP’s Health Department and QU Institutional Review Board (QU-IRB) 
approved the research proposal and the associated data collection tools (see Appendix 
B and C). Confidentiality of patients’ data was maintained, and there was no disclosure 
of any identifiers. No patient consent was sought in this phase as in most retrospective 
studies of data collection.  
 
Phase II: The Perspectives of Healthcare Professionals and Patients on the Value of a 
Collaborative Care Model for Diabetes in Primary Healthcare Settings 
Study Design 
This phase has an exploratory aim. Therefore, a qualitative approach was 
chosen, and semi-structured interviews were conducted with different HCPs and 
patients to explore their perspectives on the benefits of CCM in PHC settings. 
Qualitative research originated from social science disciplines such as sociology, 
psychology, and anthropology. It allows a deep understanding of human behavior and 
the underlying reasons, attitudes, and motivations that govern this behavior (121) rather 
than discretely explaining a phenomenon as in quantitative studies (122). However, 
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there were concerns about the robustness of this research design, which made it difficult 
to gain credibility in the health science disciplines (123). Over the past years, qualitative 
research was increasingly utilized in health literature as it succeeded in enriching the 
existing literature and led to policy and practice changes (123). Nevertheless, many 
researchers who utilized qualitative methods fail to report crucial aspects of the 
methodology (i.e. interpretative framework and philosophical assumptions) (124) and 
fail to appropriately comprehend methodological aspects of qualitative studies (e.g. 
describing “interviews” and “focus groups” as approaches to inquiry instead of data 
collection tools) (125). 
In this section, the used interpretative framework, the philosophical 
assumptions, approaches to inquiry, data collection method, data analysis, and quality 
measures will be discussed.  
 
Interpretative Framework and Philosophical Assumptions  
Several scholars, researchers, and academics including Creswell and Winit-
Watjana, Cohen, Bryman, and Silverman have defined interpretative frameworks and 
philosophical assumptions differently (126). For consistency and simplicity purposes, 
the definitions and classifications of Creswell and Winit-Watjana (126,127) will be 
considered in this study. The research question(s) must be linked to the appropriate 
interpretative framework and philosophical assumptions that will guide the study before 
selecting the appropriate approach to inquiry (125). 
 
Interpretative Framework  
Interpretative frameworks are simply the social research strategies that are 
based on the researcher’s reasoning and views of knowledge (125). According to 
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Creswell and Winit-Watjana, there are six types of interpretative frameworks as shown 
in Table 1 (126,127). 
 
Table 1. Creswell and Winit-Watjana’s Categorization of Interpretative Frameworks 
Interpretative frameworks Definition  
Positivism  Exploration of the objective reality by conducting 
theory-based research. 
Postpositivism  Conduct of research with cause and effect and a 
priori theories. 
Social constructivism  Examination of the meanings of the world in a 
complex and subjective manner, while recognizing 
the effect of researchers’ values and experiences on 
the research conduction. 
Pragmatism  Acceptance of multiple realities and proposition of 
practical solutions to the investigated problem. 
Transformative, feminist, 
critical 
Focus on developing societies and marginalized 
clusters to overcome these phenomena. 
 
Social constructivism was the most representative framework of the 
researcher’s knowledge and perceptions and the utmost appropriate one to address the 
research question. A detailed discussion of this framework will follow in upcoming 
sections. 
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Philosophical Assumptions  
Philosophical assumptions are defined as different perspectives that underline 
the interpretative frameworks selected by a qualitative researcher (128). The selection 
of appropriate philosophical assumptions guides the researchers to the suitable 
interpretative framework to follow in their qualitative research. Table 2 shows the 
questions addressed by each assumption per Creswell and Winit-Watjana 
categorization (126,127). 
 
Table 2. Creswell and Winit-Watjana's Categorization of Philosophical Assumptions 
Philosophical 
assumptions 
Questions addressed  
Ontological What is the nature of reality, being, or existence? 
Epistemological What is considered an acceptable knowledge? 
Axiological What is the influence of the researcher on attainable 
knowledge? 
Methodological What are the approaches to know the reality based on the 
researcher’s reasoning? 
 
Table 3 shows the clear distinction between interpretative frameworks based on 
their underlying philosophical assumptions (127), with clear illustrations in red under 
the selected framework (social constructivism) for this phase.
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Table 3. Interpretative Frameworks and their Underlying Philosophical Assumptions 
Philosophical 
assumptions 
Interpretative frameworks 
Positivism Postpositivism  Social constructivism Pragmatism 
Ontological  A single, objective 
and external reality 
exists with 
universal laws used 
to describe it 
 
A single reality exists 
beyond ourselves, but 
it is known only 
imperfectly and 
probabilistically 
Multiple realities are constructed through 
experiences and interactions – HCPs and 
patients had different perspectives about 
CCM because of variable demographics, 
education, and experiences. 
Reality is what is 
useful, practical and 
works well 
Epistemological Reality in the form 
of facts can be 
measured using 
reliable and valid 
tools 
 
Reality can only be 
approximated through 
research and statistics 
Reality is constructed between researchers 
and participants – The researcher negotiated 
their subjective meanings with those of the 
participants. 
Reality is known 
through objective and 
subjective evidence 
Axiological Researchers are 
independent of the 
data with an 
objective stance 
and distance 
 
Researchers’ biases 
need to be controlled 
and not expressed 
Individuals’ values are honored and 
negotiated – The researcher identified the 
influence of the diverse participants’ 
values, and identified and evaluated the 
influence of her own values and 
experiences on participants. 
Values are discussed 
reflecting knowledge 
obtained from 
researchers and 
participants 
Methodological Quantitative or 
scientific and 
predetermined 
methods, followed 
by scientific style 
of writing 
Use deductive 
methods, followed by 
scientific style of 
writing 
Use inductive methods, followed by literary 
style of writing – The researcher used 
inductive and deductive methods, asking 
participants open-ended questions and 
addressing emergent knowledge. 
Use qualitative and 
quantitative approaches 
to data collection and 
analysis 
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Approach to Inquiry: Methodology 
The selection of the methodology ensures the compatibility of the research 
questions, objectives, and methods (127). The five approaches to qualitative research 
inquiry identified by Creswell are (127):  
1. Narrative research: Describes participants’ stories regarding a phenomenon of 
interest. 
2. Grounded theory research: Generates a theory supported by participants’ data. 
3. Ethnographic research: Describes the culture of a group with shared values, 
behaviors, and beliefs. 
4. Case study research: Provides an in-depth examination of a particular phenomenon 
that researchers cannot change over time. 
5. Phenomenological research: Describes participants’ mutual experiences of a 
phenomenon. 
The aim of this research study is to explore HCPs’ and patients’ perspectives on 
the value of CCM in DM management. A phenomenological approach was chosen 
because it aims to understand the experience of participants by studying several 
individuals who shared the same experience. 
 
Study Setting 
The setting is the same as described under the “Study Setting” of Phase I. 
 
Study Population and Eligibility Criteria 
Eligible HCPs (e.g. physicians, nurses, pharmacists, and others) were those: (1) 
practicing in Qatar for at least one year; (2) working at QPDC in Dukhan; (3) involved 
in DM management within QPDC; (4) able to speak Arabic and/or English. A 
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snowballing sampling of HCPs continued until saturation was achieved. 
Eligible patients were those: (1) 18 years or older; (2) diagnosed with type 2 
DM; (3) followed up at QPDC in Dukhan; (4) able to speak Arabic and/or English. A 
purposeful sampling of patients occurred based on their background, gender, 
nationality, and willingness to participate.  
 
Data Collection Methods (Semi-Structured Interviews) 
Data collection methods can be categorized into six types: (1) observation, (2) 
documents, (3) individual interviews, (4) focus groups, (5) audiovisual materials, and 
(6) emails, chat rooms, weblogs, life journals, and instant messaging (127). For this 
phase, semi-structured individual interviews were utilized as they offer focused, 
guided, open-ended, and flexible discussions (125). The topic guide development and 
interview structure are discussed below. 
 
Topic Guide  
The interview topic guide was developed through a comprehensive literature 
review and consideration of the research objectives. The guide included open-ended 
questions with probes that triggered in-depth responses and clarifications (Appendix 
D). The guide was discussed and approved by the research team, peer-reviewed by three 
HCPs (head physician, head nurse, and head pharmacist) working at QPDC, and 
modified accordingly. Then, the interview was piloted on one HCP (pharmacist) to 
obtain feedback on clarity, inclusiveness, and appropriateness of questions.  
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Interview Structure 
Semi-structured interviews allow researchers to focus on the targeted study 
phenomena, clarify interviewee responses, discover new explanations of the 
phenomenon, and collect verbal and non-verbal communication (128). In this phase, 
semi-structured interviews were the most appropriate data collection methods. The 
interviews were conducted by the MSc student and took place in the counseling room 
at the clinic, with an average duration of 30 minutes per interview. All HCPs were 
interviewed in English, but patients were allowed to choose between Arabic and 
English. 
Recording of interviews allows researchers to obtain verbatim quotations for 
reporting the results (129). Interviews were recorded using an audio-recorder per 
participants’ consent prior to the interview. Audiotape-recorded interviews were 
transcribed verbatim; while unrecorded interviews were written as notes. Interviews 
that were conducted in Arabic were translated into English directly as they were 
transcribed. Transcribed and hand-written responses were coded into different themes 
and sub-themes using MS® Excel. Then, the coded data were analyzed systematically 
and reported.  
 
Participants and Sampling 
Semi-structured interviews were conducted with a purposive sample of 
consenting individuals to further understand their point of view regarding the benefits 
of CCM. Patients were recruited after they finished their consultation and appointment 
with the healthcare team, and HCPs were interviewed based on their availability 
between patients’ appointments. 
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The maximum variation of participants with regards to their demographics and 
experience was ensured to fully describe different perspectives and enhance the 
representativeness of the sample. Participants’ interviews continued until saturation 
was achieved and until no new themes were emergent from the responses. Interviews 
with patients took place at the QPDC counseling room; while interviews with HCPs 
took place at different locations within the center (e.g. physicians’ offices).  
 
Data Analysis 
Qualitative data analysis follows several steps including continuous revisions 
of the transcribed text, arranging and preparing data, coding, categorizing the codes into 
themes, and presenting the analyzed data as results (127) (Figure 7).  
 
 
Figure 7. Qualitative data analysis spiral. 
Source: Creswell (2018) 
 
The most commonly used qualitative data analysis methods in health science 
research are summarized below (125): 
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1. Thematic analysis: Primary data analysis that should be applied due to its flexibility 
and compatibility with various interpretative frameworks. The data generated 
through this phase was thematically analyzed. 
2. Content analysis: Comprises systematic coding followed by quantification of the 
analyzed data in a logical and unbiased way. 
3. Discourse Analysis: Emphasizes the core format and the structure of texts to 
examine the assumptions. 
 
Thematic Analysis  
Thematic data analysis was applied deductively, meaning that the study 
domains were determined a priori. The advanced features of MS® Word and 
PowerPoint were utilized to ease the process of manual coding of the verbatim textual 
transcripts. Textual transcripts of all interviews, including the pilot interview, were 
organized per participant in a single MS® Word document. The textual transcripts were 
read several times to gain familiarity with the participants' responses. Using the “Add 
Comment” feature of MS® Word, codes were added as comments to their corresponding 
meaningful phrases. It was important to use the same wordings for the same repeated 
code for tracking purposes. MS® Word was then commanded to only extract meaningful 
phrases and their codes in a separate table format. As the responses were substantial 
(i.e. resulted in 11,650 words-transcript), following other manual coding techniques 
(e.g. codes color-coding via MS® Excel (130)) were deemed impractical. Therefore, a 
novel alternative of MS® Excel was to use the “SmartArt” feature of MS® PowerPoint 
to create a visual representation of the relations between codes, and grouping of related 
codes into subthemes, themes, and finally into domains. During the reporting of the 
results, important quotes were identified and selected from the MS® Word document. 
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Quality Measures  
Similar to quantitative research, quality measures should be carefully 
considered to ensure the robustness of qualitative research. Quality measures 
or trustworthiness criteria in qualitative research are given other terms, but they 
correspond in their meaning to the terms used in quantitative research (125). These 
measures include credibility, dependability, confirmability, transferability, and 
reflexivity (125). 
• Credibility (corresponds to validity in quantitative research) ensures that results 
are valid and conclusions are credible. Credibility was maintained by having 
interviewee responses peer-reviewed at the end of the interview by the primary 
pharmacist at QPDC and by implementing appropriate data analysis methods. 
• Dependability (corresponds to reliability in quantitative research) indicates that 
research results are repeatable. A full description of the research methodology, peer 
review of the interviewee responses, and reservation of all research data in one place 
(Google drive) will allow other researchers to replicate the work in the future. 
• Confirmability (objectivity) warrants that the researchers do not influence 
participants’ perspectives. This criterion was maintained by keeping all research 
activities for future examination by other researchers.  
• Transferability (corresponds to external validity in quantitative research) identifies 
the applicability and generalizability of the research results to other settings. In 
order to achieve this criterion, a detailed description of the research setting and 
participants, and credible results interpretation was provided. 
• Reflexivity explains the researcher’s influence on the research process. Therefore, 
an occasional explanation of the researcher’s influence on the research process is 
reported in the thesis.  
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Ethical Considerations 
QP Health Department and QU-IRB approved this phase (see Appendix B and 
E). The consent form along with the information sheet including the study purpose, 
interview duration, and anticipated benefits of participation in the study was given to 
participants before the interview. Participant confidentiality was maintained by giving 
codes to respondents that were later used in data analysis and reporting. Recordings and 
transcripts were transferred to password-protected researcher’s laptop and will be kept 
for five years according to QU-IRB requirements to maintain the confidentiality and 
security of the data.  
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CHAPTER 4: RESULTS 
This chapter presents the results pertaining to this project, which aimed to (i) 
identify the impact of CCM on DM outcomes and, (ii) explore the perspectives of HCPs 
and patients on the value of CCM in primary healthcare settings. The project was split 
into two phases: Phase I – CCM’s impact on DM outcomes, and Phase II – HCPs’ and 
patients’ perspectives about the value of CCM. The results of the quantitative data 
derived from Phase I are presented, followed by those of the qualitative data from Phase 
II. 
 
Phase I: The Impact of Collaborative Care Model in Diabetes Management in a Primary 
Healthcare Setting 
Screening of Subjects for Eligibility  
A total of 325 patients’ EHR were screened for eligibility and data of interest 
were collected via the previously developed data collection sheet. Of the 325 patients, 
254 fulfilled the study eligibility criteria and were assigned into two comparison 
groups: intervention versus control groups. Seventy-one patients were excluded for one 
of the following reasons: having type 1 DM, gestational DM, or prediabetes (n=11), 
under 18 years old (n=3), irretrievable 17-months data (inadequate follow-up) (n=15), 
and have enormous missing data (n=42). 
Patients who did not receive CCM in the 17-month period were allocated to the 
control group (n=86), whereas patients who received CCM were allocated to the 
intervention group (n=168). As per the sample size calculation (see Chapter 3), each 
group should include a minimum of 82 patients. Figure 8 shows the flowchart of 
patients’ screening and allocation into the study groups. 
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Figure 8. Patients’ screening and enrolment flow chart. 
 
Sociodemographic Characteristics of Patients who Attended Qatar Petroleum 
Diabetes Clinic  
The sociodemographic characteristics of the included patients are presented in 
Table 4. Because of the retrospective nature of this phase, there were few differences 
between the two comparison groups. The control group had significantly more Qataris 
than the intervention group (p=0.006), while the intervention group significantly 
included more Indian patients compared to the intervention group (p=0.008). 
Apparently, patients in the intervention group were seen more often by HCPs compared 
to the control group as frequent follow-up visits were a vital component of CCM. 
 
Table 4. Sociodemographic Characteristics of Patients with DM Attending QPDC 
Parameter Total 
(n=254) 
Intervention 
(n=168) 
Control  
(n=86) 
P-value 
Gender, n (%)     
Male  171 (67.3) 110 (65.5) 61 (70.9) 
0.380a Female  
  
83 (32.7) 58 (34.5) 25 (29.1) 
Age in years, 
median (IQR)  
 
52 (12) 51.5 (13) 52 (12) 0.405b 
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Table 4. Sociodemographic Characteristics of Patients with DM Attending QPDC 
Parameter Total 
(n=254) 
Intervention 
(n=168) 
Control  
(n=86) 
P-value 
  
Nationality, n (%)   
   
Qatari 86 (33.9) 47 (28.0) 39 (45.3) 0.006a 
Non-Qatari     
  Indian 71 (28.0) 56 (33.3) 15 (17.4) 0.008a 
  Filipino 26 (10.2) 21 (12.5) 5 (5.8) 0.096a 
  Others 
 
71 (28.0) 44 (26.2) 27 (31.4) 
0.382a 
Number of visits, 
mean ± SD 
 
8.2 ± 3.5 10.1 ± 2.5 4.4 ± 1.3 <0.001c 
Medical history  
outside QP, n (%) 
No 225 (88.6) 152 (90.5) 73 (84.9) 0.261a 
Yes 1 (0.4) 1 (0.6) 0 (0) 
Not reported  
 
28 (11.0) 15 (8.9) 13 (15.1) 
Smoking, n (%)      
Non-smoker 215 (84.6) 144 (85.7) 71 (82.6) 
0.268a 
Ex-smoker 16 (6.3) 12 (7.1) 4 (4.7) 
Smoker 
 
23 (9.1) 12 (7.1) 11 (12.8) 
 
Alcohol  
consumption, n (%)  
Yes, regularly  2 (0.8) 1 (0.6) 1 (1.2) 
0.332a Yes, occasionally 1 (0.4) 0 (0) 1 (1.2) 
No 251 (98.8) 167 (99.4) 84 (97.7) 
aPearson Chi-square test, bMann-Whitney U test, and cIndependent Samples t-test 
were used to compute the p-values 
QP: Qatar Petroleum 
 
Baseline Clinical Characteristics of Patients who Attended Qatar Petroleum Diabetes 
Clinic 
Several of the patients followed-up at the clinic had other comorbidities 
commonly associated with DM or had DM-related complications (see Table 5). The 
three most prevalent comorbidities in the study population included: dyslipidemia 
(94.1%), hypertension (77.2%), and obesity (13.8%). Nephropathy and neuropathy 
were the most common DM-related complications reported in the study population 
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(25.2% and 21.7%, respectively). Macrovascular complications including ischemic 
heart disease, peripheral vascular disease, and cerebrovascular disease were least 
common in the study cohort (9.8%, 0.4%, and 0.4%, respectively). The comparison 
between groups showed that the intervention group did not differ from the control group 
in terms of the prevalence of DM-related comorbidities or complications, except 
coronary heart disease (p=0.046). 
 
Table 5. Baseline Clinical Characteristics of Patients with DM attending QPDC 
Parameter Total 
(n=254) 
Intervention 
(n=168) 
Control 
(n=86) 
P-value 
n (%) 
Comorbidities 
Dyslipidemia 239 (94.1) 161 (95.8) 78 (90.7) 0.100a 
Hypertension 196 (77.2) 135 (80.4) 61 (70.9) 0.090a 
Obesity 35 (13.8) 24 (14.3) 11 (12.8) 0.744a 
Asthma 29 (11.4) 17 (10.1) 12 (14.0) 0.406b 
CHD 
  
5 (2.0) 1 (0.6) 4 (4.7) 0.046b 
DM complications 
Nephropathy 64 (25.2) 41 (24.4) 23 (26.7) 0.684a 
Neuropathy 55 (21.7) 35 (20.8) 20 (23.3) 0.657a 
Retinopathy 0 (0) 0 (0) 0 (0) NA 
IHD 25 (9.8) 17 (10.1) 8 (9.3) 0.836a 
PVD 1 (0.4) 1 (0.6) 0 (0) 1.000b 
Cerebrovascular 
disease 
1 (0.4) 1 (0.6) 0 (0) 1.000b 
aPearson Chi-square and bFisher’s Exact test were used to calculate the p-values 
CHD: Coronary Heart Disease; IHD: Ischemic Heart Disease; NA: Not Applicable 
PVD: Peripheral Vascular Disease  
 
There were no statistically significant differences at baseline or at 17 months in 
the medication regimens and types of medications taken by patients in both intervention 
and control groups (Table 6). The most commonly prescribed medication regimen for 
DM in the study population was oral monotherapy. More patients in the intervention 
group received metformin than the control group at baseline (63.7% versus 54.7%) and 
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at 17-months follow-up (64.9% versus 60.5%). It was apparent that sitagliptin use 
increased from baseline to the last follow-up visit in the intervention group (9.5% 
versus 21.0%) compared to a decrease in the control group (12.8% versus 11.6%). 
Vildagliptin was not prescribed to any patient either at baseline or at 17-months. 
Similarly, no patients were treated with pioglitazone or liraglutide at baseline or 17-
months, respectively. None of the patients in the control group was prescribed 
glibenclamide at baseline or pioglitazone at 17-months. 
 
Table 6. DM Medication Regimens and Types at Baseline and at 17-Months of 
Follow Up 
 Total 
(n=254) 
Intervention 
(n=168) 
Control  
(n=86) 
P-value 
 n (%)  
Medication regimen: Baseline 
Not reported 85 (33.5) 52 (31) 33 (38.4) 0.639a 
1 OAA 82 (32.3) 57 (33.9) 25 (29.1)  
2 OAA 54 (21.3) 37 (22.0) 17 (19.8)  
3 OAA 14 (5.5) 10 (6.0) 4 (4.7)  
Insulin alone 6 (2.4) 5 (3.0) 1 (1.2)  
Insulin + 1 OAA 5 (2.0) 2 (1.2) 3 (3.5)  
Insulin + 2 OAA 4 (1.6) 3 (1.8) 1 (1.2)  
Insulin + 3 OAA 3 (1.2) 1 (0.6) 2 (2.3)  
Diet only 
 
1 (0.4) 1 (0.6) 0 (0)  
Medication regimen: At 17-months follow-up 
Not reported 65 (25.6) 36 (21.4) 29 (33.7) 0.150a 
1 OAA 88 (34.6) 65 (38.7) 23 (26.7)  
2 OAA 52 (20.5) 32 (19.0) 20 (23.3)  
3 OAA 22 (8.7) 18 (10.7) 4 (4.7)  
Insulin alone 8 (3.1) 5 (3.0) 3 (3.5)  
Insulin + 1 OAA 11 (4.3) 8 (4.8) 3 (3.5)  
Insulin + 2 OAA 6 (2.4) 3 (1.8) 3 (3.5)  
Insulin + 3 OAA 1 (0.4) 1 (0.6) 0 (0)  
Diet only 
 
1 (0.4) 0 (0) 1 (1.2)  
DM Medications*: Baseline 
Metformin 154 (60.6) 107 (63.7) 47 (54.7) 0.163a 
Repaglinide 7 (2.8) 3 (1.8) 4 (4.7) 0.231b 
Sitagliptin 27 (10.6) 16 (9.5) 11 (12.8) 0.424a 
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Gliclazide 37 (14.6) 24 (14.3) 13 (15.1) 0.859a 
Glimepiride 16 (6.3) 10 (6.0) 6 (7.0) 0.750a 
Glibenclamide 3 (1.2) 3 (1.8) 0 (0) 0.553b 
Rosiglitazone 9 (3.5) 8 (4.8) 1 (1.2) 0.280b 
Insulin  
 
18 (7.1) 11 (6.5) 7 (8.1) 0.640a 
DM Medications*: At 17-months follow-up 
Metformin 161 (63.4) 109 (64.9) 52 (60.5) 0.489a 
Repaglinide 6 (2.4) 2 (1.2) 4 (4.7) 0.184b 
Sitagliptin 45 (17.8) 35 (21.0) 10 (11.6) 0.066a 
Gliclazide 41 (16.1) 28 (16.7) 13 (15.1) 0.751a 
Glimepiride 16 (6.3) 12 (7.1) 4 (4.7) 0.439a 
Glibenclamide 3 (1.2) 2 (1.2) 1 (1.2) 1.000b 
Rosiglitazone 11 (4.3) 10 (6.0) 1 (1.2) 0.105b 
Pioglitazone 2 (0.8) 2 (1.2) 0 (0) 0.550b 
Insulin  25 (9.8) 16 (9.5) 9 (10.5) 0.812a 
* Items are not mutually exclusive 
P-values were calculated using aPearson Chi-square test and bFisher’s test  
OAA: Oral antidiabetic agent 
 
Although no randomization was required for this retrospective study, no 
significant differences were found between the two groups for all clinical parameters, 
except weight (Table 7), which was significantly higher in the control group compared 
to the intervention group (86.4 ± 19.1 Kg vs. 79.6 ± 16.5 Kg, p=0.042).  
 
Table 7. Baseline Outcome Measures of Patients with DM Attending QPDC 
Clinical parameter* Total  
(n=254) 
Intervention 
(n=168) 
Control 
(n=86) 
P-value 
HbA1c (%) 6.8 (2.5) 6.9 (2.3) 6.8 (3.4) 0.37a 
FBG (mg/dL) 130 (57.1) 130 (54.3) 128 (73.4) 0.992a 
RBG (mg/dL) 177 ± 78.7 162 ± 66.2 212 ± 96.8 0.051b 
LDL-C (mmol/L) 3.4 ± 1.6 3.4 ± 1.9 3.4 ± 0.9 0.99b 
HDL-C (mmol/L) 1.1 ± 0.3 1.1 ± 0.3 1.0 ± 0.3 0.541b 
TG (mmol/L) 1.8 ± 1.0 1.8 ± 0.9 1.9 ± 1.3 0.65b 
TC (mmol/L) 5.0 ± 1.0 4.9 ± 1.1 5.1 ± 1.0 0.257b 
SBP (mmHg) 130 ± 14.9 129 ± 14.7 131 ± 15.5 0.375b 
DBP (mmHg) 82 ± 8.5 81 ± 8.3 82 ± 9.1 0.682b 
Weight (Kg) 81.5 ± 17.5 79.6 ± 16.5 86.4 ± 19.1 0.042b 
BMI (Kg/m2) 30.7 ± 6.2 30.5 ± 6.4 31.3 ± 5.8 0.539b 
aMann-Whitney U test and bIndependent samples t-test were used to calculate the p-values 
*HbA1c and FBG are reported as median (IQR), while all other values are presented as 
mean ± SD 
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Table 7. Baseline Outcome Measures of Patients with DM Attending QPDC 
Clinical parameter* Total  
(n=254) 
Intervention 
(n=168) 
Control 
(n=86) 
P-value 
BMI: Body Mass Index; DBP: Diastolic Blood Pressure; FBG: Fasting Blood Glucose; 
HbA1c: Hemoglobin A1c; HDL-C: High-Density Lipoprotein Cholesterol; LDL-C: Low-
Density Lipoprotein Cholesterol; RBG: Random Blood Glucose; SBP: Systolic Blood 
Pressure; TC: Total Cholesterol; TG: Triglycerides 
 
Clinical Outcomes Between and Within Groups 
Although it was ideal to conduct two-way repeated-measures ANOVA to assess 
the impact of the service on two levels (i.e. the effect of group, time, and group × time 
interaction), the test was not computable because of the use of RWD that has a 
considerable amount of missing data as compared to other study designs in a controlled 
environment such as RCTs. Alternatively, within-group and between-group analyses 
were conducted separately to assess changes in outcomes of interest with time in both 
groups as presented in Table 8. Repeated measures ANOVA and Friedman tests were 
used to conduct within-group analyses for parametric and non-parametric outcome 
variables, respectively. Both tests were non-computable for weight and BMI due to 
missing data in the control group only. For between-group analyses, independent t- and 
Mann-Whitney U tests were used for parametric and non-parametric outcome variables, 
respectively (Table 8). 
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Table 8. Between and Within Group Analyses of Clinical Parameters in the Intervention Group (n=168) and the Control Group (n=86) 
Parameter Baseline 6 months 12 months 17 months P-value 
HbA1c (%), median (IQR)      
    Intervention 6.9 (2.53) 6.6 (1.34) 6.5 (1.33) 6.5 (1.18) 0.035a 
    Control 6.5 (1.90) 6.7 (2.90) 6.3 (1.00) 6.7 (2.30) 0.093a 
    P-value 0.37b 0.034c 0.282c 0.01c  
FBG (mg/dL), median (IQR)      
    Intervention 132 (60.41) 134 (34.11) 128 (30.22) 129 (47.41) 0.707a 
    Control 116 (47.84) 158 (59.96) 161 (85.85) 139  (60.82) 0.356a 
    P-value 0.992b 0.753c 0.631c 0.287c  
RBG (mg/dL), mean ± SD      
    Intervention 194 ± 72.29 158 ± 55.09 164 ± 61.14 141 ± 58.29 0.015a 
    Control 131 ± 146.53 179 ± 52.89 171 ± 100.14 196 ± 76.22 0.801a 
    P-value 0.051c 0.520c 0.993c 0.045c  
LDL-C (mmol/L), mean ± SD      
    Intervention 3.7 ± 1.07 2.1 ± 0.93 2.9 ± 0.62 2.8 ± 0.83 0.002a 
    Control 3.2 ± 0.80 2.6 ± 0.61 2.8 ± 1.11 2.7 ± 0.72 0.179a 
    P-value 0.990c 0.269c 0.087c 0.824c  
HDL-C (mmol/L), mean ± SD      
    Intervention 1.0 ± 0.20 1.1 ± 0.54 1.1 ± 0.80 1.2 ± 0.78 0.512a 
    Control 1.1 ± 0.30 1.1 ± 0.23 1.1 ± 0.30 1.0 ± 0.23 0.317a 
    P-value 
 
 
 
0.541c 0.292c 0.291c 0.097c  
  
 54 
Table 8. Between and Within Group Analyses of Clinical Parameters in the Intervention Group (n=168) and the Control Group (n=86) 
Parameter Baseline 6 months 12 months 17 months P-value 
 
TG (mmol/L), mean ± SD      
    Intervention 2.0 ± 0.94 2.0 ± 1.52 2.0 ± 1.16 1.7 ± 1.03 0.164a 
    Control 1.5 ± 0.90 1.3 ± 0.65 1.4 ± 0.70 1.3 ± 0.82 0.789a 
    P-value 0.650c 0.060c 0.883c 0.535c  
TC (mmol/L), mean ± SD      
    Intervention 5.4 ± 1.05 4.7 ± 1.30 4.6 ± 0.98 4.3 ± 1.21 <0.0001d 
    Control 4.5 ± 0.73 4.2 ± 0.86 4.2 ± 0.98 4.1 ± 0.77 0.497d 
    P-value 0.257c 0.833c 0.102c 0.317c  
SBP (mmHg), mean ± SD      
    Intervention 129 ± 14.44 129 ± 12.27 130 ± 12.27 128 ± 12.41 0.324a 
    Control 133 ± 18.36 133 ± 14.11 136 ± 18.86 136 ± 15.30 0.484a 
    P-value 0.375c 0.463c 0.188c 0.205c  
DBP (mmHg), mean ± SD      
    Intervention 81 ± 7.90 81 ± 7.48 81 ± 8.16 81 ± 9.34 0.864a 
    Control 82 ± 9.14 81 ± 7.10 83 ± 8.36 81 ± 7.93 0.385a 
    P-value 0.682c 0.626c 0.734c 0.293c  
Weight (Kg), mean ± SD      
    Intervention 79 ± 15.72 78 ± 15.94 78 ± 15.79 78 ± 15.87 0.020a 
    Control 86 ± 19.09 91 ± 17.17 86 ± 18.74 87 ± 13.10 Non-computable 
    P-value 
 
 
 
0.042c <0.001c 0.080c 0.079c  
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Table 8. Between and Within Group Analyses of Clinical Parameters in the Intervention Group (n=168) and the Control Group (n=86) 
Parameter Baseline 6 months 12 months 17 months P-value 
 
BMI (Kg/m2), mean ± SD      
    Intervention 30 ± 6.55 30 ± 6.69 30 ± 6.61 30 ± 6.82 0.010a 
    Control 31 ± 5.79 32 ± 5.09 31 ± 6.07 31 ± 4.73 Non-computable 
    P-value 0.539c 0.064c 0.420c 0.481c  
P-values were computed by aFriedman test,  bMann-Whitney U test, cIndependent t-test, and dRepeated measures ANOVA 
BMI: Body Mass Index; DBP: Diastolic Blood Pressure; FBG: Fasting Blood Glucose; HbA1c: Hemoglobin A1c; HDL-C: High-Density 
Lipoprotein Cholesterol; LDL-C: Low-Density Lipoprotein Cholesterol; RBG: Random Blood Glucose; SBP: Systolic Blood Pressure; TC: 
Total Cholesterol; TG: Triglycerides 
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Glycemic Control Parameters 
HbA1c significantly improved (i.e. reduced) from baseline to 17-months by 
0.4% within the intervention group (p=0.035). Conversely, the control group had an 
overall increase in HbA1c of 0.2% from baseline to 17-months. At 6-months and 17-
months post follow-up, HbA1c showed significant improvement in the intervention 
group compared to the control group (6 months: 6.6% versus 6.7%, p=0.034; 17 
months: 6.5% versus 6.7%, p=0.01) (Table 8). The percentage of patients in the 
intervention group who reached the target HbA1c (<7%) as recommended by the ADA 
(131) at 17-months was more than double the percentage of those who achieved the 
target in the control group (46% versus 22%, respectively) as shown in Figure 9. 
Furthermore, the average monthly HbA1c values in the intervention group remained 
fairly constant over time, while the values showed considerable fluctuations in the 
control group (Figure 10 [a]).  
Although CCM did not result in any statistical significance in reducing FBG 
either within or between groups, the intervention group had a total reduction of 2.97 
mg/dL, while the control group had an increase of 22.77 mg/dL by the end of the 17-
months follow-up period (Table 8). The values of FBG showed prominent fluctuations 
over time in the control group, with a range of 112.14–177.18 mg/dL when compared 
to 123.20–152.37 mg/dL in the intervention group (see Figure 10 [b]). RBG 
significantly improved from baseline to 17-months by 53.15 mg/dL within the 
intervention group (p=0.015), while it worsened over time in the control group. At 17-
months, the RBG was significantly higher by 54.77 mg/dL (p=0.045) in the control 
group when compared to the intervention group (Table 8). RBG of the control group 
patients had the most noticeable fluctuations with a greater maximum value compared 
to the intervention group (range: 120.12–280.30 mg/dL versus 125.31–168.92 mg/dL, 
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respectively) (Figure 10 [c]). 
 
 
Figure 9. Final mean HbA1c distribution at 17 months. 
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Figure 10. Monthly pattern of glycemic control parameters over 17 months. 
 
Lipid Profile Parameters 
The lipid profile parameters did not show significant improvement in the 
between-group analyses. LDL-C significantly improved (decreased) from baseline to 
17-months within the intervention group by 0.9 mmol/L (p=0.002) and non-
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significantly decreased by 0.5 mmol/L (p=0.179) in the control group (Table 8). The 
range of LDL-C fluctuations in the control group was similar to that of the intervention 
group at all time points (Figure 11 [a]). Additionally, HDL-C improved (increased) by 
0.2 mmol/L in the intervention group, but worsened (decreased) by 0.05 mmol/L in the 
control group over time (Table 8). Figure 11 [b] shows that HDL-C in both groups was 
fluctuating over time, with a difference in the range of 0.45 mmol/L in the control group 
and 0.38 mmol/L in the intervention group.  
CCM provision resulted in a two-fold decrease in TG by the end of the follow-
up period in the intervention group compared to the control group (0.3 mmol/L versus 
0.15 mmol/L) as presented in Table 8. Figure 11 [c] shows the prominent fluctuation in 
TG in the control group versus the intervention group, with a range of 1.46 mmol/L and 
1.12 mmol/L, respectively. Although the intervention group had a higher TC at 
baseline, TC significantly improved (reduced) within this group by 1.09 mmol/L 
(p<0.0001) over time compared to a non-significant reduction of 0.42 mmol/L in the 
control group (p=0.497) (Table 8). TC values fluctuated in both groups over the 17-
months follow-up period, with a range of 1.49 mmol/L versus 0.99 mmol/L in the 
control and intervention groups, respectively (Figure 11 [d]). 
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Figure 11. Monthly pattern of lipid profile over 17 months. 
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Blood Pressure  
SBP improved (decreased) in the intervention group by 0.8 mmHg (p=0.324), 
but worsened (increased) by 3.1 mmHg (p=0.484) in the control group at the end of 17-
months (Table 8). Figure 12 [a] clearly presents the fluctuating pattern of SBP (range: 
124.38–135.32 mmHg) in the control group compared to a relatively consistent pattern 
in the intervention group (range: 125.87–130.83 mmHg). Both groups had an 
insignificant, slight decrease (improvement) in DBP, but unlike all other parameters, 
the within-group analyses showed that the control group had a greater reduction in DBP 
compared to the intervention group (0.77 mmHg, p=0.385; 0.31 mmHg, p=0.864) 
(Table 8). Despite the better performance of the control group, DBP values showed 
greater variability in the control group, especially in the ninth and sixteenth month, 
compared to the relatively consistent fluctuations in the intervention group (Figure 12 
[b]).  
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Figure 12. Monthly pattern of blood pressure over 17 months. 
 
Anthropometric Parameters  
The weight of subjects in the intervention group was significantly reduced by 
0.67 Kg (p=0.02), compared to an increase by 0.81 Kg in the control group (p=non-
computable). At 6-months follow-up, the control group had a significantly greater 
weight by 13.01 Kg compared to the intervention group (p<0.001). Similarly, CCM 
resulted in a significant reduction in BMI of 0.25 Kg/m2 (p=0.01) in the intervention 
group compared to a reduction of 0.15 Kg/m2 (p=non-computable) in the control group 
(Table 8). Both weight (Figure 13 [a]) and BMI (Figure 13 [b]) were clearly higher in 
the control group compared to the intervention group most of the times. The control 
group had a prominently wider range of weight and BMI values (80.33–112.88 Kg and 
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29.61–39.37 Kg/m2, respectively) as compared to the intervention group (74.56–84.33 
Kg and 28.75–32.06 Kg/m2, respectively).  
 
 
Figure 13. Monthly pattern of anthropometric parameters over 17 months. 
 
Phase II: The Perspectives of Healthcare Professionals and Patients on the Value of 
Collaborative Care Model for Diabetes in Primary Healthcare Settings 
Semi-structured interviews were conducted with both HCPs and patients to gain 
an in-depth understanding of the values of CCM for patients with DM. This section will 
cover the themes that emerged from both perspectives. Although the number of 
interviewees was limited, the participants had the appropriate competence and practice 
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experiences to reflect on the explored topics. 
Twelve HCPs (two physicians, five pharmacists, and five nurses) were 
interviewed. Their mean age was 47 ± 9 years, with 8.9 ± 5 years of experience in DM 
care. The HCP group was multinational, including six Arab and six Asian HCPs (Table 
9). All HCPs were attending CPD sessions that keep them well-updated about the 
management of DM in PHC settings per the regulations of the Ministry of Public 
Health, as points systems are now a requirement for all HCPs to maintain and renew 
their license. One of the nurses is a specialized nurse DM educator; the others were 
responsible for the provision of care for patients with DM and who were frequently 
available in the clinics. 
 
Table 9. General Characteristics of Healthcare Professionals Who Participated in the 
Semi-structured Interviews on the Value of CCM in DM Care (n=12) 
HCP No. 
 
Nationality Profession Years of practice in 
DM management  
HCP 1 Qatari Pharmacy manager 5 
HCP 2  Filipino Pharmacist 13 
HCP 3 Nepalese General registered nurse  5 
HCP 4 Sudanese Pharmacist 15 
HCP 5 Egyptian Pharmacist 4 
HCP 6 Iraqi Physician  15 
HCP 7 Qatari Diabetes nurse educator 5 
HCP 8 Qatari Physician  11 
HCP 9 Indonesian Ambulance nurse 15 
HCP 10 Indian Senior nurse in charge 10 
HCP 11 Indian Pharmacist 0.6 
HCP 12 Indian Nurse 8 
HCP No.: Healthcare provider number 
 
A total of 12 patients with T2DM for an average of 8.7 ± 8 years were 
interviewed. Their mean age was 53 ± 8 years. Half of the participants were male and 
employed (Table 10).  
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Table 10. General Characteristics of Patients with DM Who Participated in the Semi-
structured Interviews on the Value of CCM in DM Care (n=12) 
Pt No. Age in 
years 
Nationality Gender Employment status Duration 
of DM 
(years) 
Pt 1 57 Indian Male Employed 6 
Pt 2 52 Sudanese Male Employed 5 
Pt 3 42 Indonesian Female Not employed 11 
Pt 4 57 Pakistani Male Employed 30 
Pt 5 61 Qatari Female Not employed 15 
Pt 6 59 Filipino Male Employed 5 
Pt 7 54 Qatari Female Not employed 11 
Pt 8 43 Indian Female Not employed 4 
Pt 9 41 Qatari Male Employed 0.5 
Pt 10 64 Qatari Female Not employed 13 
Pt 11 52 Indian  Male Employed 0.1 
Pt 12 53 Indian  Female Not employed 4 
Pt No.: Patient number 
 
HCPs’ and patients’ responses indicated that both parties have profound 
knowledge and appreciation of CCM’s positive impact on DM management and 
outcomes. Fourteen interesting themes emerged from the pre-specified four domains of 
this phase, as shown in Table 11.  
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Table 11. Domains, Themes, and Subthemes Associated with the Value of CCM in DM Management in PHC Settings 
Domains Themes Subthemes Codes 
Components of 
CCM 
Theme 1: Characteristics 
of the CCM 
 Service quality indicators • Accreditation 
• Quality care despite workload  
• Continuity of care 
• Equity of care provision 
• Prompt care provision 
 
  CCM competency • Blame-free environment 
• Patient-centered care 
• Humanistic care 
• Communication between HCPs and patients 
• Collaborative patient assessment and shared  
decision-making 
 
  Theme 2: Key players 
in the healthcare team  
HCPs’ (physicians, nurse diabetes 
educator, and pharmacists) 
personal attributes and attitudes 
 
• Awareness of CCM 
• HCPs motivation 
• HCPs job satisfaction 
• Seeking patient satisfaction 
• Patients encouragement 
• Respecting other HCPs 
• Listening to patients 
• Pleasant attitude 
• Staff having relevant credentials 
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Table 11. Domains, Themes, and Subthemes Associated with the Value of CCM in DM Management in PHC Settings 
Domains Themes Subthemes Codes 
• Competency of HCPs 
• Openness and readiness to adopt new technologies and 
research findings 
  
    HCPs’ availability and 
professionalism 
 
 
 
 
• Fixed clinic staff  
• Resolution of disagreement 
• Experience 
• Commitment and accountability  
• Trusting and accepting other HCPs 
• Understanding ones and other HCPs role 
• HCPs empathy 
• Assessment of patient’s knowledge about DM and its 
complications  
    Patients’ attributes and knowledge 
 
• Willingness and interest to receive care  
• Proactiveness 
• Adherence to medications 
• Openness to healthcare team 
• Patients part of the decision-making 
• Motivation 
• Disease self-management knowledge  
• Patient’s awareness of CCM 
  
    Involvement of family in care 
 
• Family education and counseling 
• Family support and motivation  
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Table 11. Domains, Themes, and Subthemes Associated with the Value of CCM in DM Management in PHC Settings 
Domains Themes Subthemes Codes 
  Theme 3: Coordination 
and organization of care 
process 
Accessibility • Easy access to care 
• Flexible appointment system 
    Referral and follow-up • Referral to secondary or tertiary care in emergency cases 
• Collaboration with the HR department to arrange for 
follow-up 
• Regular, frequent, individualized follow-up 
• Pharmacist-led MUR 
  
  Theme 4: Education 
and professional 
development 
Professional development and 
educational opportunities for HCP 
• Continuous professional development 
• Training/workshops on DM management 
    Patient education and counseling • Multi-perspective patient education 
• Education supported by demonstrative educational tools 
and aids 
  
  Theme 5: Managerial Technology • Computerized system 
• Glucometer software 
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Table 11. Domains, Themes, and Subthemes Associated with the Value of CCM in DM Management in PHC Settings 
Domains Themes Subthemes Codes 
support  
    Infrastructure/facilities • Private counseling room with a rounded table 
• QPDC suitable community/environment 
• The proximity of QPDC to patients 
• Free glucometer provision to all patients 
  
    Financing • Satisfying salary   
Impact of 
CCM 
Theme 1: Improvement 
in patients’ health 
outcomes 
Improved DM control  • Controlled/ improved DM outcomes 
• Modification of drug therapy, diet, and lifestyle 
• Reduction of medical errors and emergency visits due to 
uncontrolled DM 
  
Addressing patients’ 
psychological well-being 
• Overcoming patients’ panic 
Theme 2: Satisfaction 
and appreciation of 
CCM 
Patients’ satisfaction with and 
appreciation of CCM 
 
• Patients’ appreciation of CCM 
• Patients’ satisfaction with CCM 
HCPs’ satisfaction of the service • Recognition of role  
• HCPs’ satisfaction with patient improvement 
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Table 11. Domains, Themes, and Subthemes Associated with the Value of CCM in DM Management in PHC Settings 
Domains Themes Subthemes Codes 
Theme 3: Preferred care 
provider 
  • Service reputation 
• Preference for QPDC over other clinics 
• Service expansion to other QP clinics   
Facilitators Theme 1: Patient-
related facilitators 
Patients’ perceptions and attitude • Patients’ creation of a suitable atmosphere for CC 
• Patients’ active cooperation 
• The pleasant attitude of the patients 
• Patients’ pursuing health and medication education and 
information 
• Patients’ preference for fixed HCPs for the clinic 
• Patients’ familiarity with HCPs 
  
Theme 2: HCPs-related 
facilitators 
HCPs’ attributes • Following work ethics and professionalism  
• Guidelines adherence  
• HCPs’ knowledge/competence and skills  
  
HCPs’ attitudes and beliefs • Recognition of the importance of one’s role in the 
healthcare team 
• Importance of building good relations with other HCPs 
• Teamworking 
• Acceptance of other team members 
• HCPs’ interest to provide CCM 
• HCPs’ seeking patients preference 
• Pleasant HCPs attitude 
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Table 11. Domains, Themes, and Subthemes Associated with the Value of CCM in DM Management in PHC Settings 
Domains Themes Subthemes Codes 
• Satisfaction with the performance of other HCPs 
  
Theme 3: System-
related facilitators 
Administration-related factors • QP company’s encouragement and recognition of HCPs 
• Good managerial support 
• Supplies provision to uninsured patients 
• Patient privacy protection  
• The flexibility of the appointment system 
• Availability of multinational staff 
  
Resources • Printed educational material provided to patients  
Barriers Theme 1: Patient-
related barriers 
Patients’ attitudes and attributes • Lack of patients’ time 
• Communication barrier 
• Language barrier 
• Specific patient category not listening to some HCPs’ 
advice 
• Patient carelessness  
• Inadequate patients’ health literacy  
Financial barriers 
 
• Lack of insurance 
  
Theme 2: HCPs-related Workload • Lack of time and patients overload 
• Patients waiting time 
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Table 11. Domains, Themes, and Subthemes Associated with the Value of CCM in DM Management in PHC Settings 
Domains Themes Subthemes Codes 
barriers HCPs’ attributes 
 
 
• Lack of staff education 
• Lack of specialized nurse diabetes educator 
• Lack of specialized physicians (e.g. diabetologist)   
HCPs’ attitudes and beliefs 
 
 
• Unpleasant HCPs attitude 
• Attitude of physicians 
• Lack of HCPs’ interest to provide CCM 
• Underestimation of other HCPs’ role 
• Lack of respect between HCPs and patients 
• Old physicians perception of sole care provision 
  
Theme 3: System-
related barriers  
Community system • Social barrier  
Hospital system – Administration-
related barriers 
 
• Complicated appointment system 
• Infrequent follow-up 
• Unsupportive leadership 
• Lack of adequate human resources 
• Lack of confidentiality 
• Substandard medical management 
  
Hospital system – Resources • Equipment dysfunction 
• Electronic healthcare system dysfunction  
• Lack of global access to glucometer software 
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Table 11. Domains, Themes, and Subthemes Associated with the Value of CCM in DM Management in PHC Settings 
Domains Themes Subthemes Codes 
CCM: Collaborative Care Model; HCP: Health Care Professionals; MUR: Medication Use Review; QPDC: Qatar Petroleum Diabetes Clinic 
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Domain 1: Components of the Collaborative Care Model 
Theme 1: Characteristics of CCM 
Service quality indicators: Accreditation of QPDC was considered a crucial 
element in providing high-quality care. Participants explained that the prompt and 
continuous provision of equitable, high-quality care was guaranteed even in the 
presence of high workload.  
“We are following high standards of care that is acknowledged by 
management. We need to stand out in care for diabetes. It helps me to 
make people as good as they can be, which motivate us in return to give 
good service to them. We reached the diamond tier, which is the highest 
tier in the Canadian accreditation. We have comfortable environment 
and less patients, unlike Hamad, which help us to do extra work with 
less complications. We can spend one hour with one patient without 
compromising another patient. We can handle double the number of 
patients we are having now as long as the management and human 
power is more because we have to maintain our quality care” HCP 9. 
 
CCM competencies: HCPs collaboratively assess patients and make decisions 
after efficiently communicating with other HCPs and with patients. The provision of 
patient-centered care requires a blame-free, humane environment. 
“Communication between the healthcare members through ISBAR and 
with the patient directly verbal consultation. Sometimes we can send 
message from the MIMS that is very short notes that is to do something. 
But for detailed communication, we go through ISBAR by face, by 
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phone” HCP 3. 
 
“I always tell them encouraging statements like excellent and you are 
doing good. I never blame the patient even if the HbA1c is 12%, no 
problem there is a chance. The next three month we will try again and 
again. We try changing the medication. So, they appreciate this.. My 
commitment is to be human with good knowledge. I treat the patients 
as me and my kids to be treated” HCP 6. 
 
“I am living in Doha, but I come to Dukhan for my appointments. They 
care about me as a human, not as a number” Pt 9. 
 
Theme 2: Key players in the Healthcare Team  
HCPs’ availability and professionalism: There was a consensus among all 
participants that pharmacists and nurses were easily accessible. HCPs should possess 
several tenets of professionalism in order to deliver DM care. 
“We are available 24 hours; because there is no access to doctor all the 
time. And sometimes especially DM patients they have problems 
happening during the daytime, midnight, and early morning. Getting 
hypo- and hyperglycemia or other symptoms. So, it is difficult for them 
to reach doctor, but easy for them to find the assigned pharmacist. So, 
we give them our mobile number they call. Sometimes calling at 2 am, 
3 am, we are available 24 hours ” HCP4. 
 
  
 76 
“If I need anything, I call the focal pharmacist at any time. I have never 
seen a good treatment like theirs” Pt 5. 
 
“I call the diabetes nurse educator all the time when I need her. She is 
very friendly. Sometimes I do not feel good, so I come to the clinic to 
meet the team” Pt 10. 
  
“I believe that teamwork is characterized by collaboration and 
cooperation, respect, support, responsibility, continuity of care, 
working as a circle with patients centered in it” HCP 7. 
 
HCPs personal attributes and attitudes: In order to provide valuable DM care, 
HCPs must obtain valid credentials that maintain and improve their competency in DM 
management. Besides credentials, the pleasant attitude of HCPs towards their 
colleagues and patients was highly appreciated by patients.  
“HCPs should have educational background, certified certificate from a 
well-recognized institute (like being a certified DM educator, 
pharmacist and physicians must have postgraduate training in DM), 
experience, and CPD. Because if you ask me about DM management 15 
years ago it will completely be different from now (all medications, 
approaches, follow-up, and diagnostic criteria have changed)” HCP 6. 
 
“Nurses and pharmacists are very good. That is why I come for diabetes 
education. The pharmacists are very nice, and they provide 
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individualized follow-up. They are caring more. Pharmacy elsewhere 
only provides medicines, but here, doctors prescribe, and pharmacists 
help us in medications” Pt 11. 
 
Patients’ knowledge and attributes: Patients’ knowledge about the disease, 
medications, and CCM facilitates collaboration in the healthcare environment. 
Participants expressed that vigilance and proactiveness of patients are essential 
attributes to better health outcomes. The deliberate negligence of health education by 
patients contributed negatively to their disease condition and overall health.  
“The patient has to be compliant, adherent to medications and attend 
follow-up appointments, read a little about his disease, find out what is 
his/her concerns, fears, worries, because we ask them, and they should 
know. In Canada, a 10-years-old patient has access to FDA [Food and 
Drug Administration] and new medications and they discuss with me 
regarding the new medications. We provide them education, but they 
have to read something. The patient must have commitment to care for 
themselves, now the approach is patient-centered” HCP 6. 
 
Involvement of family in care: Active family participation in DM self-care in 
the form of group meetings with HCPs leads to better health outcomes as the family is 
considered one of the key players in the management of DM. 
“We have a private consultation room with rounded table, because 
sometimes we call families not only patients for family meetings to 
provide special services to them like education because families need 
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our support” HCP 4. 
 
“I believe that the family of the patient is the most important key player 
in the medical team” HCP 8. 
 
Theme 3: Coordination and Organization of the Care Process 
Easy access to organized care: Patients have easy access to all HCPs during 
appointments and walk-in visits. Within a single visit, patients have to see mainly their 
physician, pharmacist, and nurse for an overall assessment of their status. In addition, 
the participants generally indicated satisfaction with the organized process of care in 
the clinic as supported by the below statements. 
“We have easy access and lovely care we are taking. We are familiar 
with each other. Each one of them know us very well, other places they 
need to go through cases. They are providing good advices also” Pt 1. 
 
“The pharmacist checks my glucometer readings and recommends 
changes in medicines if needed. The nurse educates me about diet and 
exercise and checks my vital signs. The doctor makes tests, even if the 
glucose readings are regular” Pt 8. 
 
“It is very easy for patients to reach the doctor and the focal point 
pharmacist; they can text him or come immediately” HCP 5. 
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HCPs encourage patients to visit the clinic or contact them by phone in case of 
facing difficulties in DM management. Patients of all nationalities frequently contact 
pharmacists and nurses by phone to inquire about medication dose adjustments (e.g. 
insulin) after deviating from the meal plan.  
 “Usually we tell them if they have any doubts or questions just call at 
any time and we give them our phone even after office work and 
weekends. They also can come at any time, especially the newly 
diagnosed patients, and we tell them if you have any queries come any 
time just give them the time frame we are open and tell them do not 
hesitate to call us any time if it is needed” HCP 2. 
 
 “We have flexibility. We recommend having appointment strictly. If in 
urgent case, they can walk-in at any time. If you provide good care to 
patient you will have job satisfaction, we don’t base our work on fast, 
we base our work on satisfaction and quality care” HCP 3. 
 
“We encourage patients to come at any time even if the visits is not 
scheduled or leave a message” HCP 7. 
 
Follow-up and referral: The clinic receptionist arranges frequent appointments 
for patients with DM based on their case, but rarely less than four visits a year. The 
majority of patients are followed up on a monthly basis. In the case of advanced DM 
complications, HCPs refer patients to secondary or tertiary care as needed.  
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“The doctor encourage me to come for follow-up visit once every month 
and more often at any time if I need more help” Pt 12. 
 
“If it an urgent case, we may refer the patient to secondary care for 
hospitalization in case of severe hypo-/hyperglycemia, concern about 
DKA [diabetes ketoacidosis] or HSS [hyperosmolar hyperglycemic 
state], or acute complications of diabetes” HCP 6. 
 
Theme 4: Education and professional development 
Professional development and educational opportunities for HCP: DM 
management is continuously changing with the emergence of new treatment 
approaches. Effective DM management requires HCPs to remain updated with all new 
treatments, technologies, and modalities through obtaining credentials or attending 
educational sessions about DM management. 
“HCPs should have educational background, certified certificate from a 
well-recognized institute (like being a certified DM educator, 
pharmacist and physicians must have postgraduate training in DM), 
experience, CPD because if you ask me about DM management 15 years 
ago it will completely different from now.. all medications, approaches, 
follow-up, and diagnostic criteria changed” HCP 6. 
 
Patient education and counseling: Patient education is viewed as a cornerstone 
of DM management as it empowers patients to appropriately self-manage themselves, 
which eventually contributes to the improvement of glycemic control, QoL, and 
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reduction of long-term implications. All HCPs provide consistent advice to patients 
about DM and their medications at each visit that reduced patients’ confusion till the 
next appointment. 
“Patient education is the first step for us. After that, we ask for MUR 
[Medication Use Review], we ask the patient to bring all what he is 
taking from different location or from his country, even herbal products 
if he is taking. We ask them to bring and we try to know how he use all 
these medications and then we check patient file from electronic 
profile... It is very good for patients health because patient is hearing 
advices from all collaborative team care. By increasing patient 
knowledge and patient education, the most important point, patient 
after that starts to cooperate and build a trust between the healthcare 
team and the patient” HCP 4. 
 
“The team care is very good for patients health specially if they have 
diabetes because we always need support from them. I feel that I can 
confidently manage my blood sugar and my health because of the 
education they provide me with” Pt 12. 
 
Theme 5: Managerial Support  
Technology: HCPs expressed the need for unbiased education by medical 
representatives about new medications and technologies. The management at QPDC 
provides HCPs with the required technologies that facilitate care provision to patients 
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with DM. All patients are provided with the newest glucometers that can be linked to 
HCPs’ computers. 
“They provide us with mobiles, technology, free glucometers for 
patients” HCP 7. 
 
Infrastructure/facilities: The management also supports the health staff by 
providing them with a dedicated counseling room used for patients and family meetings 
and counseling. This counseling room maintains patients’ privacy and ensures their 
comfort throughout the duration of the visit. 
“All infrastructure is evident including this room which gives patients 
privacy” HCP 2. 
 
“They are giving full support. We have a private consultation room with 
rounded table ... with suitable, comfortable chairs and education tools” 
HCP 4. 
 
Financing: QP company covers all health expenses of employees. Even non-
QP employees who are not insured still receive part of care free of charges like the 
glucometer and its strips. However, they are charged for other aspects of the service.  
 “In QP, some patient are not covered financially for the service and they 
need the service. We still give them glucometer and strips, because it is 
difficult for them to purchase” HCP 4. 
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Domain 2: Impact of Collaborative Care Model on Diabetes Outcomes 
Theme 1: Improvement in Patients’ Health Outcomes 
Improved DM control: Participants indicated that before the launch of the 
service, the incidence of DM emergency visits due to hypo- and hyper-glycemia at QP 
Medical Center in Dukhan was high. After the implementation of CCM, HCPs 
followed-up patients closely (face-to-face and by phone) in order to tailor and modify 
their drug therapy regimens, diet, and lifestyle based on their glycemic control. Hence, 
medical errors and emergency visits due to fluctuations in blood glucose levels were 
noticeably reduced. 
 “I deal with patients with hypo- and hyperglycemia; we give them 
education. Before the clinic, these incidents were very high. But after 
patients are followed-up in the clinic, they have less fluctuations in their 
blood glucose level… Now we rarely have emergency cases because of 
the good service patients receive at the clinic” HCP 9. 
 
 “We, the pharmacists, do counselling, MUR, answer questions of 
patients because doctors sometimes are busy, educate about food and 
diet. After seeing results of patients, patients are happier and may be 
discontinued from 2-3 medications because of the improvements” HCP 
11. 
 
“They gave me good diet and I am almost stopping NoVo rapid and the 
HCPs team became very happy” Pt 1. 
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Addressing patients’ psychological well-being: A minority of patients 
expressed their concern when dealing with apathetic physicians in other PHC centers 
who raise their anxiety levels regarding their health status. Patients with DM, especially 
if newly diagnosed, need supportive healthcare staff who will calm them down and 
enhance their self-confidence. 
“A lot of patients who come with HbA1c 12%, reach 7% and feel much 
better. Even their spirit, they feel like they are doing very good job. This 
is our job to support and promote the patient. I always tell them 
encouraging statements like excellent and you are doing good. I never 
blame the patient even if the A1c is 12%, no problem there is a chance. 
Next three month we will try again and again” HCP 6. 
 
“Some doctors will make you panic, so I went to the focal pharmacist 
because of the panic they caused me. The staff is very friendly because 
they will calm us down and reduce our panic. Here they are very friendly 
using psychological approach” Pt 11. 
 
Theme 2: Satisfaction and Appreciation of CCM 
Patients’ satisfaction with and appreciation of CCM: Engaging patients in the 
decision-making process makes them satisfied with the collaborative care provided. 
Patients appreciate the useful information about health and medications provided to 
them by HCPs that are otherwise not provided at other PHC centers or hospitals.  
“When we provide the service for the patient, most of them are feeling 
happy. When patient starts to work with us and starts to build trust 
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between us, immediately asking why when we go to other healthcare 
centers or hospitals they are not telling us like that. It is the very first 
time for us to hear this information. They are saying this to doctors, 
nurses, and pharmacists” HCP 4. 
 
“I feel committed and happy to do my job. The appreciation and "thank 
you" from patients make us satisfied (not only the salary)” HCP 10. 
 
“I cannot see any barrier. We are lucky to have a good service here” Pt 
4. 
HCPs satisfaction: HCPs, especially pharmacists, were satisfied when their role 
was recognized by patients and other members of the healthcare team. The 
improvements in patients’ health after receiving the CCM boosted the satisfaction of 
HCPs.  
“I feel happy and satisfied when I see progress in their [patients] health 
and lifestyle” HCP 5. 
 
“When I get a good lab result they become very happy and you can see 
that from their face” Pt 1. 
 
Theme 3: Preferred Care Provider 
Patients showed their preference for the care received at QPDC over other 
clinics due to the visible health outcomes they experienced. Patients are advising family 
and friends to follow-up at this clinic, which enhanced its reputation in the city and at 
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the management level. Therefore, the management of QPDC is interested in expanding 
the service to other QP health centers in Qatar to reduce the burden of DM on the 
economic and healthcare system.  
“Some patient are coming from Doha to receive this service. See how 
many centers and hospital in Doha. Even locals are moving from Doha 
to here to receive DM care” HCP 4. 
 
 “I only follow-up with this clinic. Even if they are on vacation, I wait 
until they come back. I do not go to other clinics. I feel that I can control 
my disease if I follow their advice. They encourage me to follow their 
advices every visit. I will be harmed if I follow-up in other clinics because 
I got used to all the HCPs here as a group” Pt 5. 
 
“I don’t go to any other clinic. I was going to QP Doha wellness center 
until 2008, then I came here” Pt 7. 
 
Domain 3: Facilitators to Collaborative Care Model 
Theme 1: Patient-related facilitators 
Patients’ perception and attitude: Patients became familiar with the healthcare 
team and therefore made the collaboration easier. Patients also indicated that having 
fixed healthcare staff for their case management was a factor in optimal DM care. HCPs 
expressed their motivation to collaborate when they deal with patients of pleasant 
attitude, cooperative manners, and adequate health literacy. Patients believed that it is 
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their responsibility to create a suitable atmosphere for HCPs to help them collaborate 
effectively.  
“High knowledge about the disease and medications, bringing their 
glucometer, and the willingness to receive the care keep us motivated” 
HCP 12. 
 
“We have to create the good atmosphere for them. Because they are 
human beings and they are caring for us. When they spend a lot with a 
patient we should wait and not get angry because HCPs are not telling 
stories, they are giving medicines. We should have good attitude 
towards them” Pt 4. 
 
Theme 2: HCPs-related facilitators 
HCPs attributes: In order to provide the best collaborative care to patients with 
DM, competent HCPs must first possess adequate knowledge, have a professional set 
of skills, and have the interest to provide collaborative care. Not to mention, following 
work ethics that are set by the health management at QP company as well as 
international practice guidelines can positively influence the provision of CCM. 
“The professions working in the team must be competent, well-
educated, and have a desire to help the patient” HCP 1. 
 
“Holistic and cooperative approach has criteria that must be met like 
having a good physician, understanding pharmacist, educated nurse” 
HCP 6. 
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HCPs’ attitudes and beliefs: The recognition of the importance of one’s role in 
the healthcare team and acceptance of other team members' contributions led to greater 
HCPs’ satisfaction and recognition of the importance of building good relations with 
other HCPs and team work to improve CCM provision. Patients recognized that HCPs 
who are interested in their work are more likely to be pleasant and seek patients' 
preferences when making decisions. 
“Knowing that my role is important increases my passion to collaborate 
and provide education to patients who have gap in knowledge” HCP 11. 
 
“The doctor supervise the treatment plan, discuss, hear me, and talk 
friendly. The pharmacist doesn’t refuse anything I ask for, he also 
discusses with me in a friendly language. The nurses are patient with us 
and educate us” Pt 5. 
 
Theme 3: System-related facilitators 
Administration-related factors: The good managerial support at QP company 
recognizes the efforts of HCPs and encourages them to collaborate. Having 
multinational healthcare staff facilitates effective communication with patients of 
different languages. One of the repeatedly mentioned facilitators by the majority of 
participants is the flexibility of the appointment system that provides HCPs with close 
monitoring of patients' cases and quickly addresses patients’ healthcare needs. Patients' 
openness and trust in HCPs was greatly facilitated by their privacy protection. The 
management also ensures supplies provision even to uninsured patients, representing 
an universal approach to care delivery. 
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 “QP company facilitates and encourages us to give our best” HCP 9. 
“Flexibility in appointment system, lead clinic in this area, cooperation, 
update staff, shared decision making with HCPs and patients, and 
privacy” HCP 7. 
 
“They have a very flexible appointment system that works well with our 
duty times” Pt 9. 
 
Resources: The availability of resources, including educational materials and 
technologies given to patients, facilitates the provision of collaborative care to improve 
their knowledge and ability to self-manage their condition, respectively. 
“They [the management] provide us with mobiles, technology, free 
glucometers for patients” HCP 7. 
 
“If we request some printed materials (brochures) they [the 
management] will provide” HCP 5. 
 
Domain 4: Barriers to Collaborative Care Model 
Theme 1: Patient-related barriers 
Patients’ attributes and attitudes: One barrier identified by HCPs is interacting 
with illiterate patients, especially geriatrics, or foreigners. Patients who are careless 
about their health and accepting recommendations only from physicians impose a great 
obstacle to the provision of CCM by HCPs. Dealing with patients who lack time to 
receive the full process of care compromises some steps of care over the other. 
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 “If patients are careless, we will not be able to help them. In the 
meantime, it is up to the patient. We provide them with everything, but 
if they insist not to care and hurt themselves it is up to them. But we still 
need to find out why.” HCP 6. 
 
“Barriers include [...] lack of patient time, lack of patient education 
specially geriatrics” HCP 7. 
 
Financial barriers: HCPs have an ethical responsibility to ensure that all 
patients have access to needed care regardless of their economic background or status. 
HCPs and QPDC management address patients' financial barriers by discussing 
insurance issues with patients and justifying patients’ needs to the corresponding 
insurance company. 
“In QP, some patient are not covered financially for the service and they 
need the service. We still give them glucometer and strips, because it is 
difficult for them to purchase, we are trying to manage them for one 
month” HCP 4. 
 
“The supply and cost of medication: They have a limited quantity to 
supply to patients. If they exceed, insurance may object so they have to 
give an explanation” Pt 1. 
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Theme 2: HCPs-related barriers 
Workload: Physicians' desire to collaborate with other HCPs is not always 
sufficient for providing CCM. There was a consensus that physicians always suffer 
from patient overload in non-collaborative health environments. High patient load 
limits the time allocated for patient-provider interaction, hence, proper assessment and 
treatment. Patient overload also lengthens the wait time for patients to access the needed 
healthcare. 
“Doctors would like to collaborate, but they have a time pressure. They 
don’t have the chance to work with a team. They have a lot of patient 
load. We can make awareness for people regarding this issue” HCP 1. 
 
HCPs attributes: The lack of enthusiastic, interested, and educated healthcare 
providers hinders the provision of quality care to patients with DM. Having more staff 
possessing specialized credentials (e.g. specialized diabetes educators) was perceived 
as necessary for the continuity of care provision, especially in the absence of other 
specialized co-workers. Moreover, participants indicated that there is a need to have 
specialized physicians (e.g. diabetologist, ophthalmologists) at PHC settings to 
eliminate the need for referring patients to other hospitals. 
 “Lack of interest. So many times, I ask about the reason but no reply. If 
talking about overload, sometimes we are two people working here, 
one covering two windows and the other one covering the diabetes 
clinic patients. Patients are still satisfied and not complaining. If we go 
for statistics, every year no one is complaining against pharmacy. So, 
the workload is not a cause for that” HCP 4. 
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“Some nurses don’t have specialized diabetes courses. If they have, that 
will be very good in case the other specialized nurse is on leave” HCP 
10. 
 
HCPs’ attitudes and beliefs: Some physicians at other clinical settings 
persistently believe that doctors should be the sole caregivers and decision-makers, 
which does not guarantee the provision of comprehensive care. Patients expressed 
frustration with the hierarchical behavior of physicians when receiving care at other 
healthcare centers or hospitals. 
 “Sometimes each HCP have their own mind, but here we hear from 
others and share new studies done. Even if we disagree, we try to reach 
one final decision at the end. Sometimes they underestimate other 
members of the team” HCP 5. 
 
“HCPs who think that they are smarter than patients, and not using 
good terms when communicating with patients and with each other” Pt 
6. 
 
“Shortage of staff, and having the classic opinion that doctors are the 
only HCP that should work with patients and make decisions” HCP 8. 
 
Theme 3: System-related barriers 
Community system: As strong social relationships positively impact patients' 
health, the opinion of inexperienced individuals regarding health and medications are 
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taken seriously by many patients. Patients' obedience to such opinions interferes with 
professional HCPs' advice they receive, thus leading to adverse health outcomes. 
“We have social problem here, especially in gulf areas, people they trust 
what their community is telling them not take insulin because some 
people took it and died or have kidney problems. So, patients trust their 
acquaintances blindly. Unfortunately, this is the biggest problem we are 
facing” HCP 4. 
 
Hospital system – Administration-related barriers: The lack of adequate human 
resources, especially during holiday seasons, may lead to the discontinuity of care 
provided to patients in need. Substandard and unsupportive leadership was identified 
by participants as a barrier to healthy collaboration. Complicated appointment systems 
at healthcare institutions contribute to infrequent follow-up and management of patients 
with DM. Patients indicated that the lack of confidentiality of their suggestions and 
discussions in the healthcare environment might harm their career. 
“A bad management system can discourage everyone from healthy 
collaboration. In governmental health centers, the appointment system 
is very complicated. But they solved the issue by having a separate 
department working on arranging appoints. It is a little better now. 
They will give an appointment every three months and in case of 
urgency, you will get an appointment after a month” Pt 9. 
 
“Healthy discussions between patients and doctors and pharmacists 
may improve our case. Non-anonymous discussion and suggestion may 
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harm my job” Pt 11. 
 
Hospital system – Resources: HCPs indicated that comprehensive care 
provision is not possible in the case of dysfunction of electronic healthcare systems and 
tools (e.g. glucometer). Although QPDC provides patients with glucometers that are 
linked to the MIMS system, the lack of global access by other healthcare institutions to 
glucometer software is another identified barrier to CCM provision. 
“There can be economic barriers like equipment. If the equipment is not 
working properly, improvement will not be distinguished. Even if not 
calibrated properly, that can also be a barrier to healthcare provision” 
HCP 3. 
 
“Not having a glucometer software that connects with different types 
of health systems” HCP 8.
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CHAPTER 5: DISCUSSION AND CONCLUSION 
Investigating the impact of collaborative healthcare has become increasingly 
important for decades in an effort to lessen the burden of chronic diseases including 
DM. International organizations concerned with the management of DM have reported 
a high prevalence of DM and its complications despite the advancement in healthcare. 
To our knowledge, this is the first study conducted in Qatar to investigate the impact 
and value of CCM in primary care settings. The aim of this project was to address the 
following research questions: What is the impact of CCM of DM-related outcomes and 
what are the perspectives of HCPs and patients on the value of CCM in DM care in 
PHC settings?  
This chapter interprets the key findings of the study and discusses the 
significance of the findings in the context of the existing body of literature. First, the 
discussions focus on Phase I of the study, and later divulge into Phase II of the study. 
 
Phase I: The Impact of Collaborative Care Model on Diabetes Outcomes in a Primary 
Healthcare Setting 
This study showed the impact of CCM on 11 DM-related outcomes over a 
period of 17-months. Given that the literature assessing the impact of CCM on diabetes 
outcomes took place over different study periods, a similar fashion will be followed in 
comparing the magnitude of improvement in the outcomes over the follow-up period. 
In the present study, reductions in HbA1c were both clinically and statistically 
significant. The CCM provided at QPDC resulted in a significant reduction in HbA1c 
by 0.4% within the intervention group from baseline to 17-months (p=0.035). The 
significant reduction in HbA1c after receiving interventions from different healthcare 
team members in PHC settings reported in several studies ranged from 1.2%–2.1% in 
shorter periods (minimum 8 months) compared to the current study (17 months), which 
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could be due to inherent differences in the nature and intensity of the intervention 
provided or the study design used (94–96,112,132–138). Few studies conducted in the 
MENA region have shown similar positive clinical improvements in HbA1c, FBG, lipid 
profile, and DM self-care activities after receiving pharmacists interventions as part of 
a collaborative healthcare team (95,139). Davis et al. (94) found  that 23.4% of patients 
who received the intervention met the goal HbA1c of <7% compared to 46% of patients 
who received CCM in our study. The majority of the cited studies have linked the 
outcomes improvements to the educational interventions on health, diseases, 
medications, and lifestyle provided by the healthcare team. Compared with DM 
management in the hospital setting, PHC centers yielded better clinical outcomes and 
patients’ satisfaction according to an observational cohort study involving 1678 patients 
with DM conducted in Qatar (140). Provider–patient communication in PHC was 
shown to be associated with better glycemic control among patients with type 2 DM 
(141). Moreover, it was found that lower socioeconomic status worsened glycemic 
control and physical and mental health (142). At QPDC, most patients either have QP 
insurance or are covered by different types of health insurance, giving them adequate 
access to healthcare. Interestingly, healthcare services were provided to certain extent 
for patients without insurance.  
Although FBG did not show statistically significant improvements between and 
within groups in the current study; the FBG improved from baseline to 17 months by 
2.97 mg/dL in the intervention group, whereas deterioration occurred in the control 
group by 22.77 mg/dL. Some studies found a greater reduction in FBG in the 
intervention group within a shorter follow-up period (95,112,143). An improvement in 
FBG (reduction of 17.7–53 mg/dL) in patients who received collaborative care 
compared to usual care over 6 months of follow-up was reported in the literature 
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(95,143). FBG was significantly improved in another study of a one-year follow-up 
duration by 16.6 mg/dL in the intervention group (112). 
Lipid profile (LDL-C, HDL-C, TG, TC) showed improvements in the 
intervention group over the study period. This is in line with the results reported in the 
short-term and long-term Asheville projects, where an improvement in lipid profile was 
evident at every follow-up but with a small magnitude that did not reach statistical 
significance (136,137). Usually, lipid profile parameters require a prolonged follow-up 
period to show significant reductions compared to the baseline. On the other hand, a 
six-month follow-up study revealed a significant improvement in lipid profile in both 
the intervention group and the control group, but no significant differences were seen 
in the between-group analyses (95). In the current study, TC, LDL-C, and HDL-C 
improved by 0.46 mmol/L, 0.53 mmol/dL, and 0.2 mmol/L, respectively in the 
intervention group over 17-months. These findings were consistent with a cross-
sectional study conducted at QP Messaied Medical Centre that reported a significant 
improvement in the mean TC, LDL-C, and HDL-C by 0.39 mmol/dL, 0.2 mmol/dL, 
and 0.04 mmol/dL, respectively in patients attending a special DM clinic versus 
receiving care at a non-specialized PHC clinic (115).  
Although CCM did not result in statistically significant improvement in SBP, 
there was a clinical improvement (reduction) in the intervention group by 0.8 mmHg, 
while there was an increase in SBP by 3.1 mmHg in the control group. The control 
group had a non-significant greater reduction in DBP by 0.77 mmHg compared to 0.31 
mmHg in the intervention group during the follow-up period. Previous studies have 
reported a greater significant improvement in SBP and DBP by 4.9–12.1 mmHg and 
2.3–7.2 mmHg, respectively over a shorter follow-up period (94,140). According to 
ADA, the target SBP and DBP in patients with DM and hypertension should be <130/80 
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mmHg (144). Patients who received CCM had mean SBP and DBP values at goal 
during the four time-points (except baseline DBP value), whereas patients in the control 
group had not. Patients having a more poorly controlled blood pressure might 
experience greater reductions in blood pressure as a result of receiving collaborative 
care compared to those having a current blood pressure closer to target. The lack of 
significance could also result from the high standard deviation of subjects’ blood 
pressure values. 
The baseline body weight value was higher in the intervention group than the 
control group. However, this difference in body weight between the two groups was 
lost after three months of follow up period (p=0.08). At the end of the follow-up period, 
patients receiving CCM had a significant reduction in their weight by 0.67 Kg (p=0.02), 
while the control group patients had an increase in body weight by 0.81 Kg (p-value 
not available). The literature reporting the impact of collaborative care on weight is 
conflicting due to the different the follow-up periods of each study. For example, one 
study conducted over four months showed that the intervention resulted in no change 
in weight reduction within and between groups (145). Another study followed patients 
for six-months yet reported an increase in weight by 2.7 Kg in the intervention group 
(143). Furthermore, BMI significantly improved within the intervention group only by 
0.25 Kg/m2 (p=0.010) from baseline to 17-months. A greater significant reduction in 
BMI of 1.7 Kg/m2 (p=0.001) was reported in a study of shorter follow-up period (i.e. 
12-months) (112). Other studies have shown that components of CCM including 
medication management, educational interventions, and patient reminder systems had 
resulted in statistically significant improvement in BMI by 0.6 Kg/m2 in the intervention 
group (96,146). 
Although no statistically significant differences were noted in medication 
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regimens between the two groups, CCM improved medication use and optimized 
therapy according to guidelines and patients’ needs. There was an increase in the 
addition of insulin to one oral antidiabetic agent (OAA) in the intervention group 
compared to the control group. Neto et al reported no effect of pharmacists 
interventions as part of the healthcare team on the mean number of medication used per 
patient in both groups (p=0.092) (147). The investigators reported only the mean 
number of drugs used in the last month of the 36-month study, which might not reflect 
the differences in the utilization of medications in the intervention group compared to 
the baseline, and whether the pharmacist helped in switching patients to a more 
appropriate medication regimen or not.  
 
Phase II: The Perspectives of Healthcare Professionals and Patients on the Value of 
Collaborative Care Model for Diabetes in a Primary Healthcare Setting 
To our knowledge, this was the first study in Qatar to investigate the 
perspectives of patients with DM and HCPs providing care for those patients regarding 
the value of CCM in DM management in PHC settings. As one previous research 
suggested, the introduction of new working relationships may not always be successful 
due to the lack of demonstrable achievements and poor role definitions as well as poor 
relationships (23). Therefore, it is logical to explore the perspective of key stakeholders 
regarding the introduction of CCM for DM in a PHC setting.  This phase supports the 
development and implementation of CCM in DM management in PHC settings in 
Qatar. 
Fourteen interesting themes have emerged from participants’ responses in this 
phase classified under four domains: components of CCM, the impact of CCM, 
facilitators to CCM, and barriers to CCM.   
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The primary reason why patients prefer QPDC is the availability of unique 
characteristics exclusive to this clinic. Patients perceived the easy access to qualified 
HCPs, the easy arrangement of follow-up visits, and receiving special health education 
as important determinants to manage their condition. Participants in one study were 
also aware that knowledge and education alone is not sufficient to manage DM safely 
and effectively (148,149). Moreover, the participants indicated that having fixed HCPs 
at QPDC enhanced their familiarity with HCPs and strengthened patient-provider 
relationships on a personal level. A qualitative study reported that patients usually meet 
different HCPs when visiting DM clinics and that they perceived staff alternation as a 
barrier to continuity of care (115). Patients who did not have a fixed DM healthcare 
team were frustrated and more likely to have lower medication adherence and worse 
health outcomes (20,150–152). One study highlighted that patients from racial and 
ethnic minority groups were less likely to have a consistent provider, and were more 
likely to experience problematic communication with HCPs (20,153,154), which was 
not evident among patients attending QPDC. A study reported that both patients and 
PHC providers preferred to have the same diabetes team as this promoted familiarity 
between both parties and contributed to consistency in care provision (23). Patients 
preferred to develop a relationship with educators and appreciated being cared for by a 
familiar team of HCPs (23) who are like a “family member” to them (20). Patients’ 
satisfaction, confidence, trust toward the HCPs, and adherence to medications were 
evident when patients had a familiar healthcare team (115). 
Both patient and HCP participants expressed the importance and value of 
collaboration in the healthcare environment, which ultimately reflects the harmony in 
the provision of care to patients with DM. Clinical interactions among HCPs created 
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new knowledge and understanding of the patient, thereby enabling the provision of 
individualized patient care (23).  
Formal and informal communication was frequently valued as a crucial 
component of CCM by both patient and HCP participants as it reflects on the quality of 
the care delivery and patients’ familiarity with the healthcare provider. Communication 
between HCPs and patients in-person and through technology-facilitated medium helps 
in creating strong professional and personal relationships between them. Studies have 
shown that familiarity and informal interactions (e.g. personal interactions during 
lunch, providing corridor consultations, etc) have promoted personal exchange, 
encouraged intergroup relations, enhanced the understanding of each profession’s 
approaches, and clearly defined different professional priorities of different HCPs 
(155,156). Furthermore, HCPs recognized that face-to-face meetings facilitated the 
provision of better patient-centered care and facilitated timely responses during 
patients’ follow-up while patients were still on site (23). Conversely, the lack of 
informal relationships was shown to disconnect HCPs from their healthcare team (23), 
and that is why interpersonal communication was referred to as the ‘glue’ of 
multidisciplinary collaboration (157).  
Both patients and HCP participants indicated that effective and continuous 
communication between HCPs and patients enabled close monitoring of patient’s 
condition and adherence to personalized treatment plans, leading to the detection of any 
alarming health issues. Communication is an effective tool to close the gap between the 
patient’s healthcare needs and the HCPs’ expectations, thereby facilitating the 
provision of patient-centered care in DM management that is tailored to patients’ 
cultural values, beliefs, knowledge, and expectations (19,20,158,159). Similarly, HCPs 
should avoid giving instructions to patients, but instead encourage healthy discussions 
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and respect patients’ concerns, as this would be a more useful way to correct the 
patients’ understanding of DM and gain their cooperation (19).  
The study participants have identified other modes of communication in the 
healthcare environment including the use of MIMS, emails, and administrative staff. 
As indicated by HCPs, especially nurses, the MIMS system allowed them to share 
patient information instantly. Accordingly, a few DM educators indicated that EHR 
notes were one way to share patients’ information and care recommendations such as 
lifestyle or BG monitoring with other HCPs (23). The participants clearly expressed the 
importance of different means of communication that facilitate CCM, which was 
opposed by one study that showed that participants considered these means of 
communication less effective for team functioning (80). Pharmacists at QPDC were 
proud of utilizing the best technologies including audiovisuals in patient and family 
education. Providing health education to patients and their families, rather than 
individually, using audiovisuals and printed educational material were considered as 
important tools in improving patients’ knowledge and understanding about DM (19). 
Another component of CCM is the recognition of each healthcare team 
member’s role by patients and HCPs. HCPs, especially pharmacists, expressed their 
enthusiasm and satisfaction in their job when they felt that their role is appreciated by 
other team members and by patients. Certified diabetes educator pharmacists practicing 
in Canada expressed that the greatest personal benefit resulted from the increased job 
satisfaction and sense of workplace (160). Patients were extremely confident in the 
knowledge, ability, and role of the pharmacist to educate them on insulin therapy 
adjustment based on self- monitoring of BG (161). 
Additionally, participants recognized the importance of relevant HCPs’ 
education, clinical experience, and attitude. The inclusion of DM nurse educators 
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within the DM healthcare team was perceived as crucial for the continuity of care to 
patients with DM. Considerable evidence showed that the involvement of specialized 
nurses in DM care led to better health outcomes compared to traditional physician-led 
care (19,162). In fact, having several certified DM educators was suggested as a 
solution to the shortage of DM nurse educators at QPDC particularly during vacations. 
Nurses have been trained to sustain the management of DM elsewhere especially in the 
absence of healthcare teams (23). Another HCPs’ attribute is their interest in DM. Many 
HCPs indicated that their interest in managing DM is their main motivation to 
effectively collaborate with other HCPs and to provide optimal care to patients with 
DM. Physicians participating in one qualitative study also indicated that HCPs should 
have ‘a personal interest’ in DM care and show this interest to patients (19).  
Participants indicated that the pleasant and flexible attitude of HCPs facilitates 
communication and collaboration with patients and other HCPs. Our findings were 
similar to the literature reporting that HCPs being ‘flexible’, ‘easy-going’, and 
‘confident’ are necessary characteristics to consider the HCP as a valuable team player 
(23). Participants also indicated that there is a great need for a strong relationship 
building with other healthcare team members through regular meetings and discussions 
to provide better DM care to patients. The literature showed that a crucial component 
to enhancing working relationships is to build trust and rapport among HCPs through 
regular meetings and on-site discussion when the care is being provided to patients (23). 
Regularly scheduled meetings and case discussions were shown to optimize the 
efficiency of healthcare teams in meeting patients’ needs and addressing operational 
challenges (80,163). 
Patients’ attributes and attitudes were other identified component of CCM. 
Patients tend to focus on their experience of illness, while HCPs focus on the 
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physiological aspects of illness and its management (20). Although both aspects are 
important to patients’ health and well-being, differences in views can result in 
communication misalignment (20,153). In the present study, participants indicated that 
there is a need for efficient communication and education to reach a common ground. 
Therefore, HCPs must include patients in the decision-making process to facilitate 
shared goals, better adherence, and potentially better health outcomes (20). In our 
qualitative study, all participants appreciated the inclusion and engagement of patients 
in shared decision-making in DM management, which made them feel that they are 
“treated humanely”. In several studies, patients expressed a desire to be "perceived as 
individuals, not illnesses" and indicated that they felt “reduced to their disease” when 
HCPs exclusively focus on solving medical problems (164). HCPs in the current study 
felt that the provision of engaging, respectful, and humane healthcare was their 
responsibility. 
Regarding the impact of CCM, it was recognized that there was a perceived 
increase in patients’ satisfaction and QoL as well as an improvement in patient health 
after receiving CCM. Other studies have reported similar results, but quantitatively 
(143,161,165). For example, Mast et al reported a significant improvement in patients’ 
satisfaction with their current DM treatment (p=0.006), the amount of time taken to 
manage their DM (p=0.043), and the frequency of feeling physically ill (p=0.025) on 
the QoL questionnaire administered to patients who received baseline usual care (pre-
test) then received collaborative care (post-test) (143). Another impact of CCM 
reported by the participants is the reduction of emergency department visits due to DM-
complications. HCPs have observed that the initiation of the service had resulted in a 
reduction in emergency visits at QPMC, which was similar to the findings of a cross-
sectional study conducted in the United States (161). 
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Both HCPs and patients were able to recognize that the outcomes of DM 
management can be influenced by several factors related to patients, HCPs, and the 
healthcare system. Participants have identified a lack of patient’s time, carelessness, 
inadequate patients’ health literacy, communication barrier, language barrier, and lack 
of insurance as barriers to CCM provision to patients with DM at PHC settings. Several 
barriers to the provision of CCM for patients with DM have been identified in the 
literature as well. For example, HCPs who participated in one study were frustrated 
with patients’ poor adherence to a healthy lifestyle and medications recommended by 
the healthcare team, especially older and uneducated patients (19). They used 
expressions such as ‘the patients are not listening’, ‘not understanding’ or ‘not 
following the instructions’ (19). Similar to our findings, the participants of the former 
study indicated that older and uneducated patients with DM were not willing to follow 
physicians’ recommendations or attend health education (19). Physicians and nurses in  
the same study also expressed a higher probability of medication misuse and non-
adherence by patients who fear harm or damage to their body organs (19), a finding that 
was contrast to our findings, where patients showed no concern for DM consequences 
as they felt adequately educated and managed at QPDC. Most of the HCPs in our setting 
emphasized the importance of having a multi-national healthcare team to be able to 
understand and interact with patients of all ethnic/racial backgrounds. Non-Arabic 
speaking physicians participating in one study expressed language barriers with patients 
who could not speak English, which forced them to communicate with family members 
or asked for the assistance of other HCPs for translation and interpretation (19). 
One of the HCPs-related barriers recognized by patients is lack of allocating 
sufficient time for consultation by HCPs, resulting in a lack of adequate patient 
education and counseling on self-management. Other studies showed that patients also 
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frequently complained that providers “go too quickly” (150) and do not have time to 
get to know them and their concerns (19,20,164).  
HCPs recognized lack of trust and appreciation of other team members’ roles as 
a barrier to the provision of CCM in other PHC settings. This could be more prominent 
among new team members because their professional competency and ability had yet 
to be demonstrated (19,23,166). Another study showed that new educators felt like 
“outsiders” and tentatively build rapport while simultaneously avoid hindering the daily 
routine at the practice settings (23). However, mutual respect and understanding of 
others’ role were the most important factors for promoting effective service integration 
among all HCPs involved in caring for patients with DM (23). The increase in 
familiarity among HCPs suppresses professional boundaries and hierarchies and 
encourages collaboration, thus enhance trust (23). Some physician have related the lack 
of collaboration in the healthcare environment to mistrust of the competences of the 
other HCPs, knowing that the complexity of DM care necessitates a sharing of 
responsibility between HCPs (167). The cause of this mistrust could be the lack of 
appropriate IPE to HCPs during their university years. IPE is considered an important 
component in building capacity and developing collaborative practice-ready health 
professionals who are competent in delivering CCM (168).  
Despite the increasing prevalence of DM, inadequate reimbursement of 
comprehensive DM care is frequently reported in the literature (169–171). HCPs 
perceived that most of the services needed by patients with DM are inadequately 
reimbursed, which limits their ability to perform all the tasks necessary to deliver 
comprehensive DM care (169). Even in a fee-for-service environment that rewards 
volume over quality, HCPs indicated that they cannot afford to provide collaborative 
DM care to all patients with DM, despite their willingness and interest to do so (20,115). 
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At QPDC, reimbursement was not perceived as a concern, probably because of the 
adequate financial support. HCPs working at QPDC had an interest in and ability to 
provide CCM regardless of financial return. 
The lack of teamwork approach and shortage of human resources were 
recognized by HCPs as system-related barriers to CCM in PHC settings. Previous 
researchers found that physicians indicated that they had to do everything for the 
patients due to lack of DM specialist nurses, shortage in the number of dieticians and 
health educators, and no podiatrists for foot care (19,115).  
The participants in this study (HCPs and patients alike) recommended some 
solutions to improve the provision of CCM to patients with DM. They believed that 
there should be a flexible and proactive appointment call center that arranges frequent 
follow-up visits, hence reduce patients’ overload. Patients’ overload may place HCPs 
under undue pressure to shorten duration of consultations, resulting in suboptimal DM 
control and increased risk of DM-related complications (19). Physicians indicated that 
it is very important to see a reasonable number of patients such as 10 – 15 in order to 
provide optimal DM care (172,173). Reducing the workload and number of visits of 
patients positively affected HCPs’ performance and attitudes according to a study 
conducted in DM clinics in Oman (19).  
 
Strengths and Limitations of the Study 
There are several strengths as well as limitations in this study that are 
noteworthy; therefore, the findings should be interpreted in light of these. This study is 
the first of its kind to robustly investigate the impact of CCM on DM-related outcomes 
and the perspectives of HCPs and patients on the value of CCM in a PHC setting in 
Qatar. Although an RCT is the preferred study design to investigate the cause and effect 
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of interventions or treatments, the use of RWD in Phase I of this study reflected a more 
naturalistic, non-controlled environment that is more representative of the target 
population. Interestingly, the RWE generated from this project showed similar results 
to numerous published RCTs, despite the potentials for lower medication adherence 
and other factors that were expected to lower the effects of the intervention. 
Furthermore, Phase I of the study had a relatively large sample size that ensured 
adequate power to detect a difference in DM-related outcomes. Despite having an 
unequal number of patients in each group, the variances between groups were equal in 
ten out of eleven parameters. This study also included a comparison group and 
evaluated multiple outcomes related to DM and other comorbidities. Finally, this study 
supports the initiative to implement CCM in DM management in PHC settings in Qatar 
that is aimed to reduce the disease burden. 
Although health literature is heavily reliant on quantitative data, human's unique 
experiences and different perspectives cannot be neglected. The coalition of HCPs’ and 
patients’ perspectives in Phase II allowed the generation of in-depth understanding and 
authentic conclusions regarding the value of CCM in DM management. Key guidelines 
on qualitative research conduct were thoroughly reviewed and considered to ensure the 
proper implementation of this phase. The qualitative data obtained from the participants 
provided more detailed, powerful, and compelling results based on stakeholders’ 
experiences and observations, and revealed the value of CCM that cannot be 
investigated quantitatively. All HCP participants were familiar with the researcher and 
were consistent in the information being provided, obviating the concern of data 
manipulation by the researcher. Moreover, choosing interviews over other data 
collection methods (e.g. focus groups) was more suitable to the sensitive setting at 
QPDC. Quotes identification and reporting were revised several times by the 
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supervisors to ensure transparency and eliminate any emergent bias that could be 
introduced by the researchers. We have strengthened the credibility of this study by 
interviewing participants of diverse sociodemographic characteristics to introduce 
variability to the study sample and answer the research questions from different 
perspectives. Although qualitative data extrapolation from the study group to the 
general population may not be always feasible, there is still an opportunity to create 
generalizations from the data reported in this study due to the various purposive 
sampling technique used. Through in-depth interviews, we identified facilitators and 
barriers to CCM provision in PHC settings for patients with DM, which can guide 
health policymakers to consider both factors when implementing CCM.  
This study has certain limitations, some of which are inherent to the respective 
types of the study designs utilized. First, Phase I was a study of a retrospective design, 
which is susceptible to a lack of adequate documentation of essential information/data 
such as medications, diagnoses, and complications. Second, incomplete and 
inconsistent data was one of the major limitations of this phase. This resulted in 
inapplicability of analyzing the data using two-way repeated-measures ANOVA test. 
Third, patients with type 1 DM were excluded from the study due to their insufficient 
number (n=3). Fourth, blind assignment of participants to groups was not applicable 
due to the retrospective nature of the study; however, this was not considered a concern 
as patients’ natural assignment in the real-world has circumvented the potential bias 
associated with the lack of blinding. Fifth, other relevant data such as patients' 
medication adherence that may affect the studied clinical outcomes were not available; 
hence, those moderating and confounding variables were not accounted for in this 
study. Finally, the dates of diabetic foot examinations, comprehensive eye 
examinations, and influenza immunization status were not collected due to inconsistent 
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documentation among patients, and the performance of these tests elsewhere (e.g. 
nearby governmental hospitals that use different electronic health systems). 
Likewise, Phase II of the study had some other limitations to be considered. 
First, the presence of the researcher during the interviews might have created some 
anxiety in a minority of the participants. Participants' anxiety was addressed by 
allocating adequate time to establish rapport before the interview. Second, there was an 
issue of anonymity and confidentiality while presenting the findings as the sample size 
is relatively small and participants could be identified by others through their 
demographics. This drawback was unavoidable since the patient population and human 
resources for health (i.e. the numerical strength of HCPs) at the QPDC are very limited. 
Third, the purposive sample was determined based on HCPs' recommendations, which 
could introduce bias beyond the researcher's awareness. Fourth, the researcher's 
perspective and observation were not extensively tracked, yet all supervisors had access 
to all transcripts and were actively engaged in data interpretation and reporting process 
to enhance transparency. Finally, the study is limited to one geographical location (i.e. 
Dukhan); nevertheless, the findings can be transferable to other similar settings.   
 
Future Directions and Recommendations 
The current study provides a basis for future research studies. Further research 
is warranted to evaluate the level of involvement of different HCPs that produces the 
greatest improvement in the health outcomes of patients with DM in PHC settings. 
Future work should be conducted to address how cultural competencies and diversities 
among HCPs and patients impact interprofessional team care. There is also a need to 
investigate the effect of CCM on patient-reported outcomes including, but not limited 
to, QoL, satisfaction, preference, perceived treatment burden, and others. Furthermore, 
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economic evaluations (e.g. cost-benefit analysis, cost-effectiveness analysis, and cost-
utility analysis) of the impact of CCM on DM-related outcomes in PHC settings are 
also warranted. Predictions of the impact of CCM on future disease prevalence can add 
value to the available literature. Given the magnitude of the impact of CCM on DM 
outcomes in PHC settings, it is reasonable to utilize the approach in managing patients 
with type 1 DM as well as other chronic diseases and other settings (e.g. secondary and 
tertiary healthcare settings). Continuous education of HCPs and patients will narrow 
the gap between current practice and the optimal implementation of CCM, therefore 
improve and sustain health outcomes. Knowing that poor glycemic control is the most 
determinant of diabetes-related complications and death (174), further evaluation on 
the impact of improved glycemic control by CCM on DM-related complications is 
demanded. Finally, health policymakers and administrators in the PHC sector should 
explore the potentials of applying this practice based on the generated evidence that 
may result in improving healthcare outcomes and decreasing the burden associated with 
DM.  
 
Conclusions 
Inefficiencies in delivering DM care in PHC settings can be circumvented by 
the integration of CCM. Phase I of the present study evaluated the impact of CCM on 
several DM-related outcomes in PHC settings, and has demonstrated several significant 
improvements in DM-related outcomes including HbA1c, RBG, LDL-C, TC, weight, 
and BMI when patients with DM received collaborative care. The findings of Phase I 
support the important role of the PHC setting in DM management and highlight the 
positive impact of the integration of different HCPs into the healthcare team in PHC 
settings on tangible health outcomes. Successful implementation of CCM could lead to 
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a decrease in the workload, reduction in the frequency of emergency department visits, 
improvement in DM-related outcomes, hence a decrease in morbidity and mortality 
associated with DM complications. To the best of our knowledge, Phase II of this 
project is the first study conducted in Qatar to investigate and report the positive 
perspectives of patients and HCPs on the value of CCM for managing DM in PHC 
settings. Important components of CCM such as HCPs’ and patients’ attributes and 
attitudes, family involvement in the care process, availability of technology, and 
utilization of facilities were recognized by the participants. The provision of CCM may 
promote patients’ health, level of patients and HCPs satisfaction, and preference of the 
service over other forms of care. To facilitate collaborative practice in similar settings, 
pleasant attitudes of patients and HCPs besides administrative support through tangible 
resources must be considered. However, unpleasant attitude and undesirable attributes 
of HCPs and patients, unsupportive hospital system, and high workload were some of 
the identified barriers to CCM provision to patients with DM in PHC settings. 
Understanding of the complexity of factors that influence CCM provision for patients 
with DM in PHC settings provides HCPs and health policymakers with future 
directions.  
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